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ABSTRACT 
Although previous research has indicated that hormone replacement therapy benefits memory in 
menopausal women, several newer studies have shown no effect or detrimental effects. These 
inconsistencies emphasize the need to evaluate the role of hormones in protecting against age-
related cognitive decline in an animal model. Furthermore, research has found that ovarian 
hormones alter brain structure and function. However, many studies evaluating the effects of 
estrogen and progesterone on brain structure have used young adult animals and have not 
administered medroxyprogesterone acetate (MPA), the most commonly prescribed progestin. 
The aging brain may respond differently to the presence of these hormones. Therefore, the 
effects of long-term hormone treatment during aging on cognition and neuroanatomy were 
investigated. Female Long Evans hooded rats were ovariectomized at middle age (12-14 months) 
and placed in one of 5 groups: no replacement, chronic estrogen only, chronic estrogen and 
progesterone, chronic estrogen and MPA, and cyclic estrogen. Hormone treatment continued 
until sacrifice. Estrogen was administered in the drinking water. Progesterone and MPA were 
administered with subcutaneous pellets. Following five months of hormone replacement, animals 
were tested on a delayed alternation task in the T-maze. Two weeks after completing the T-maze 
animals were tested in the Morris water maze. At approximately 20 months of age, animals were 
sacrificed and their brains were sectioned and using immunohistochemistry, stained for tyrosine 
hydroxylase and synaptophysin. Adjacent sections were Nissl stained to calculate volume and 
quantify neuron number. The medial prefrontal cortex was examined because it is involved in 
several cognitive tasks and is known to be sensitive to both aging and ovarian hormones. Using 
unbiased stereology and light microscopy, neuron number and synaptophysin labeled boutons 
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were quantified. Images were acquired of the tyrosine hydroxylase sections using Axiovision 
(Zeiss) on a fluorescent microscope and fiber densities were quantified.  
Behavioral results found that animals receiving estrogen in combination with MPA acquired the 
t-maze faster than no replacement animals, but there were no differences in performance on the 
delayed portion of the task. However, on the Morris water maze, animals receiving this hormone 
treatment were impaired as compared to other hormone treated groups. Estrogen in combination 
with MPA resulted in greater synaptophysin levels in the medial prefrontal cortex. Analysis of 
tyrosine hydroxylase fibers found that animals receiving estrogen in combination with MPA 
consistently had significantly higher tyrosine hydroxylase pixel densities than no replacement 
animals. Hormone treatment did not significantly alter neuron number in the medial prefrontal 
cortex.  
These results indicate that the effects of long-term hormone treatment are task specific and long-
term hormone treatments alter dopaminergic functioning and synapse number in the medial 
prefrontal cortex, providing a possible mechanism by which long-term hormone treatments can 
influence cognition. Importantly, these beneficial neural outcomes were observed in groups 
receiving estrogen in combination with the controversial progestin, MPA. 
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PREFACE 
Menopause in humans is associated with a loss of ovarian hormones and this decline in estrogen 
and progesterone has been linked to several of the symptoms related to menopause.  Hormone 
therapies including Premarin (conjugated equine estrogens; CEE) and Prempro (CEE in 
combination with medroxyprogesterone acetate; MPA), have been approved to alleviate these 
symptoms. In women with a uterus, MPA, a synthetic analogue of progesterone, is administered 
in combination with estrogen therapy to prevent endometrial hyperplasia (Whitehead, King, 
McQueen, & Campbell, 1979). Along with alleviating some of the symptoms of menopause, 
studies have found beneficial effects of hormone treatment on cognition (Joffe et al., 2006; Krug, 
Born, & Rasch, 2006; LeBlanc, Janowsky, Chan, & Nelson, 2001). However, results from the 
Women’s Health Initiative, indicate that CEE alone or CEE administered with MPA results in an 
increased risk of stroke, and dementia (Anderson et al., 2004; Anderson et al., 2004; Shumaker et 
al., 2004; Wassertheil-Smoller et al., 2003). Whether hormone treatment alters brain structure or 
has beneficial effects on cognition during aging has recently become a topic of debate.  
Indentifying the underlying mechanisms that contribute to cognitive changes occurring during 
aging provides potential targets for treatments aimed at protecting against this age-related 
decline.  However, there are many factors that may affect the neural and behavioral outcomes of 
hormone replacement during aging, including, whether or not estrogen is combined with 
progesterone and if so the type of progesterone used, natural or synthetic, the mode of 
administration, length of hormone deprivation, and route of administration. 
Studies have found that different combinations of hormone treatment do not always result in 
similar outcomes. The addition of progestogens can result in different results from estrogen only 
treatments. Progesterone completely reversed the beneficial effects of estrogen on the water 
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maze so that middle-aged animals receiving both estrogen and progesterone did not differ from 
animals not receiving hormone replacement (Bimonte-Nelson, Francis, Umphlet, & Granholm, 
2006). Also, the type of progestogen used can influence the outcome and many animal studies 
that have evaluated the effects of progestogens on cognition have used progesterone rather than 
MPA, the most commonly prescribed progestin. While MPA is a synthetic analogue of 
progesterone and is an agonist at progesterone receptors, it also binds to androgen and 
glucocorticoid receptors (Bamberger, Else, Bamberger, Beil, & Schulte, 1999; Bardin, Brown, 
Isomaa, & Janne, 1983). Some argue that natural progesterone may be more beneficial than 
MPA. One study found that progesterone was neuroprotective in vivo while the synthetic 
progestin MPA was not (Ciriza, Carrero, Frye, & Garcia-Segura, 2006), indicating that the type 
of progesterone used could determine whether the result of hormone replacement is beneficial. A 
recent study found that MPA administered without estrogen impaired performance on the water 
radial arm maze and the water maze (Braden et al., 2010).   
Another factor that may influence the outcomes observed with hormone treatment is the mode of 
replacement. It is possible that cyclic hormone replacement may be more beneficial than chronic 
hormone replacement because it more closely resembles the natural cycle of hormones. The 
studies that have investigated the effects of repeated cyclic hormone treatment are inconsistent. 
Weekly injections of estradiol plus progesterone enhanced performance of aged female rats on a 
delayed match-to-position T-maze task (Gibbs, 2000) and in aged rhesus monkeys, cyclic 
estradiol cypionate injections improved spatial working memory performance (P. R. Rapp, 
Morrison, & Roberts, 2003). Two other studies have found that both continuous and intermittent 
estradiol significantly improved task acquisition in middle aged and aged animals (Bimonte-
Nelson et al., 2006; Markowska & Savonenko, 2002). However, cyclic administration of 
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estradiol benzoate did not improve performance in middle-aged female rats on a 12-arm radial 
arm maze (Ziegler & Gallagher, 2005). Furthermore, while continuous estradiol treatment had no 
effect on spatial working or reference memory in the radial arm maze, intermittent estradiol 
treatment impaired spatial reference memory (Gresack & Frick, 2006). Although the results of 
these studies differ, most of the studies that have attempted to mimic the natural cycle of 
hormones have only simulated certain aspects of the cycle. It is possible that more closely 
simulating the natural cycle by including fluctuations in both estrogen and progesterone levels 
may be more beneficial than the chronic treatment of ovarian hormones. 
Recently the length of hormone deprivation has been extensively studied. This research has 
indicated that there is a “window of opportunity” meaning that waiting too long after menopause 
or estropause in rats, to begin hormone replacement could lead to the replacement having no 
effect on cognition.  In the Women’s Health Initiative previously discussed, the ages of the 
subjects ranged from 65-79 which may be too late to begin hormone replacement in order to 
have beneficial effects on cognition. There is evidence that the timing of hormone replacement 
onset is an important factor and may explain the negative findings of the Women’s Health 
Initiative studies (Gibbs, 2000; Sherwin, 2009). In a study by Gibbs (2000), animals that had 
hormone replacement initiated immediately following ovariectomy or within three months of 
ovariectomy performed significantly better than controls, while animals that received hormone 
replacement 10 months after ovariectomy showed no significant differences from controls. 
Recent work indicates that the ability of estrogen to enhance synaptic communication in the 
hippocampus depends on the length of hormone deprivation not the age of the animal 
(McLaughlin, Bimonte-Nelson, Neisewander, & Conrad, 2008; C. C. Smith, Vedder, Nelson, 
Bredemann, & McMahon, 2010).    
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Oral administration is the most common route of administration of hormone treatment in post 
menopausal women. Animal studies more commonly use injections or silastic capsules to deliver 
hormone treatments. These routes of administration have different pharmacokinetics than oral 
administration and do not allow for first pass metabolism of the hormone which may result in 
different outcomes of hormone treatment. Indeed, the only study that has administered estradiol 
orally and examined effects on cognition in an animal model found improved performance on 
object recognition (Fernandez & Frick, 2004), while another study from the same lab found that 
daily injections of estradiol did not improve performance on the same task (Gresack & Frick, 
2006). Therefore it is important to evaluate the effects of hormone treatment using a route of 
administration that is similar to the most common route used by post-menopausal women. 
Although studies have attempted to address some of these factors, few have looked at the effects 
on hormone replacement in conjunction with one another. Several questions remain regarding 
the effects of hormone treatment on the structure and function of the brain during aging. 
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INTRODUCTION 
In humans, aging is almost always accompanied by a decline in cognitive abilities. For women 
this decline has been associated with menopause. Several studies have found that women who 
receive estrogen replacement show improvement on a wide variety of cognitive tasks including 
tests of memory (reviewed by LeBlanc et al., 2001). However, others have found little or no 
cognitive benefit of when women were given estrogen only or estrogen plus 
medroxyprogesterone (Hogervorst, Williams, Budge, Riedel, & Jolles, 2000; Yaffe, Sawaya, 
Lieberburg, & Grady, 1998). Although the hippocampus has long been presumed the primary 
site of action of estrogens on cognition, research indicates that the prefrontal cortex (PFC) may 
be important as well (Joffe et al., 2006; Kampen & Sherwin, 1994; Keenan, Ezzat, Ginsburg, & 
Moore, 2001; Krug et al., 2006). 
Like humans, rodents experience age-related cognitive decline, and thus provide models for 
testing the role ovarian hormones may play in cognition during the aging process. Estradiol or 
estradiol benzoate treatment in both middle aged and aged female rodents often improves 
performance on the water maze (Frick, Fernandez, & Bulinski, 2002; Frye, Rhodes, & Dudek, 
2005; Harburger, Bennett, & Frick, 2007; Markham, Pych, & Juraska, 2002) however see 
(Foster, Sharrow, Kumar, & Masse, 2003). Although our lab previously found that chronic 
treatment with ovarian hormones improves performance on the water maze, a hippocampal 
dependant task, (Markham et al., 2002), prior to the study presented in chapter 1, it was not 
known how estrogen in combination with MPA would affect performance on this task. Also, this 
was the first study to examine the effects of long-term chronic hormone treatment on the water 
maze. 
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Studies have also found improved performance after estrogen treatment on several other tasks 
including the radial arm maze, spontaneous alternation, and both delayed matching to position 
and delayed non-matching to position tasks (Gibbs, 2000; Heikkinen, Puolivali, & Tanila, 2004; 
Markowska & Savonenko, 2002; M. M. Miller et al., 1999). However, some studies have found 
that the behavioral outcome of hormone treatments depends on the type of task used (Frye & 
Walf, 2008). Whether the hormone combinations used in Chapter 1 would result in a similar 
outcome on delayed alternation, a task mediated by the PFC, was evaluated in Chapter 2.  
Research indicates that the PFC may be an important site for estrogen’s actions on cognition 
(Keenan et al., 2001) and this brain region seems to be particularly vulnerable to aging. For 
example, brain metabolism is decreased during aging and the medial PFC experiences the largest 
decline (Pardo et al., 2007) and this brain region has greater decline in gray matter volume than 
other brain areas (Raz et al., 2005; Resnick, Pham, Kraut, Zonderman, & Davatzikos, 2003). 
Studies have found several cellular changes that could accompany this change in volume 
including, cell loss, reductions in dendritic material, and alterations to neurotransmitter systems 
(Cupp & Uemura, 1980; de Brabander, Kramers, & Uylings, 1998; Duan et al., 2003; Grill & 
Riddle, 2002; Inoue et al., 2001; Jacobs, Driscoll, & Schall, 1997; Kaasinen et al., 2000; 
Kaasinen et al., 2002; Markham & Juraska, 2002; Mizoguchi, Shoji, Tanaka, Maruyama, & 
Tabira, 2009; Wallace, Frankfurt, Arellanos, Inagaki, & Luine, 2007). Importantly, there have 
been few studies evaluating the effects of long-term chronic hormone treatment on the structure 
of the mPFC during aging. MRI studies in humans have found that hormone treatment decreases 
the shrinkage associated with aging of both the cortex and hippocampus (Boccardi et al., 2006; 
Lord, Engert, Lupien, & Pruessner, 2010; Resnick et al., 2009; Robertson et al., 2009). It is not 
possible to observe the structural changes that may be occurring at the cellular level in the human 
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MRI studies; however, in young non-human primates, estrogen treatment increases spine 
synapse density in the PFC (Hao et al., 2006; Leranth, Hajszan, Szigeti-Buck, Bober, & 
MacLusky, 2008; Tang et al., 2004), indicating that estradiol may affect the number of synapses 
in the aged PFC. In rodents, ovariectomy decreases spine density in the rat mPFC (Wallace, 
Luine, Arellanos, & Frankfurt, 2006) and intact females lose fewer spines during aging in the 
medial prefrontal cortex (mPFC) than males which may be due to the continued secretion of 
estrogen and progesterone during estropause (Markham & Juraska, 2002). Studies indicate that 
estrogen alters spines in the hippocampus of young animals, but it is unknown if estrogen alters 
synapses in the aging rat mPFC. In addition, comparison of the effects of different progestogens 
has not been conducted. Chapter 3 examines the effects of different hormone formulations during 
aging on synapses in the mPFC.   
Changes in several neurotransmitter systems could underlie the effects of hormone treatment on 
synapse number.  However, the dopaminergic system is important for prefrontal functioning and 
altered with aging. Furthermore, studies suggest that ovarian hormones also affect dopaminergic 
function. Low dose estrogen treatment increased dopamine levels in postmenopausal women 
(Zarate, Fonseca, Ochoa, Basurto, & Hernandez, 2002) and in non-human primates, ovariectomy 
reduced, and estrogen replacement restored the density of axons stained for tyrosine hydroxylase 
in the dorsolateral PFC (Kritzer & Kohama, 1998). In rats, estrogen treatment influences the 
dopaminergic system (Inagaki, Gautreaux, & Luine, 2010; V. N. Luine, Richards, Wu, & Beck, 
1998; McDermott, 1993). However, it is currently unknown how long-term hormone treatment 
alters dopaminergic functioning in the mPFC. Chapter 4 examines the question of whether 
hormone treatment during aging alters the density of dopaminergic fibers in the mPFC. 
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An alternative mechanism by which hormone treatment decreases shrinkage associated with 
aging is by preventing neuron loss.  Studies have found a loss of cortical neurons in humans 
(Pakkenberg & Gundersen, 1997), rhesus monkeys (D. E. Smith, Rapp, McKay, Roberts, & 
Tuszynski, 2004), and rats (Yates, Markham, Anderson, Morris, & Juraska, 2008) during aging. 
There is evidence from our lab that this loss is sexually dimorphic with males but not females 
losing neurons during aging in the mPFC (Yates et al., 2008). The presence of ovarian hormones 
may protect females from this age-related loss. In addition, estrogen and progesterone have been 
shown to have neuroprotective properties in vitro; however, MPA counteracts the 
neuroprotective effects of estrogen (Nilsen & Brinton, 2002b). Currently, it is unknown what this 
might mean for neuron number during aging. Chapter 4 also examined neuron number in the 
mPFC after long-term chronic exposure to these hormones. 
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CHAPTER 1 
LONG-TERM REPLACEMENT OF ESTROGEN WITH MEDROXYPROGESTERONE 
IMPAIRS PERFORMANCE ON THE MORRIS WATER MAZE IN MIDDLE AGED 
FEMALE RATS 1
                                                          
Previously published as: Lowry NC, Pardon LP, Yates MA, Juraska JM (2010) Effects of long-
term treatment with 17 beta-estradiol and medroxyprogesterone acetate on water maze 
performance in middle aged female rats. Horm Behav 58:200-207  
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Abstract 
Although previous research has indicated that hormone replacement therapy benefits memory in 
menopausal women, several recent studies have shown either detrimental or no effects of 
treatment. These inconsistencies emphasize the need to evaluate the role of ovarian hormones in 
protecting against age-related cognitive decline in an animal model. The present study 
investigated the effects of long-term hormone treatment during aging on the Morris water maze. 
Female Long Evans hooded rats were ovariectomized at middle age (12-13 months) and were 
immediately placed in one of five groups: no replacement, chronic 17 β-estradiol (E2) only, 
chronic E2 and progesterone, chronic E2 and medroxyprogesterone acetate (MPA), or cyclic E2 
only. E2 was administered in the drinking water in either a chronic or cyclic (3 out of 4 days) 
fashion. Progesterone and MPA were administered via subcutaneous pellets. Following 6 months 
of hormone treatment, animals were tested on the Morris water maze. Animals performed four 
trials a day for 4 days and after the final day of testing a subset of animals completed a probe 
trial. Across 4 days of testing, rats receiving E2 in combination with MPA performed 
significantly worse than all other groups receiving hormone replacement. In addition on the last 
day of testing, chronic E2 administration was more beneficial than cyclic administration and no 
replacement. Thus, compared to other hormone-treated groups, long-term treatment with E2 in 
combination with MPA resulted in impaired performance on the spatial Morris water maze. 
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Introduction 
A decline in many cognitive abilities accompanies aging in humans. For women, this decline has 
been associated with the decrease in ovarian hormones that occurs during menopause (Nappi et 
al., 1999; Sherwin, 1988). Numerous studies have reported an improvement in cognitive 
performance of women receiving hormone treatment (reviewed by LeBlanc et al., 2001). For 
example, hormone treatment enhances measures of verbal memory and improves performance on 
tasks of spatial and verbal working memory (Carlson & Sherwin, 1998; Duff & Hampson, 2000; 
Kampen & Sherwin, 1994). However, other studies have found little or no cognitive benefit of 
hormone treatment in postmenopausal women (reviewed by Hogervorst et al., 2000). The 
Women’s Health Initiative found that conjugated equine estrogen alone or administered with 
medroxyprogesterone acetate (MPA), the most common progestin given to women, failed to 
enhance cognition and increased the number of subjects diagnosed with either probable dementia 
or mild cognitive impairment in post menopausal women (Espeland et al., 2004; S. R. Rapp et 
al., 2003; Shumaker et al., 2003; Shumaker et al., 2004). These conflicting results emphasize the 
need to determine the factors influencing whether hormone replacement benefits or impairs 
cognition.  
Studies investigating the association between hormone treatment and cognition in humans 
contain confounds which can be manipulated or controlled in a rodent model. Rodents 
experience age-related cognitive decline and thus may provide useful models for explaining the 
role ovarian hormones play in cognition during the aging process. However, most research 
investigating the effects of hormone treatment on cognition has used young animals (reviewed in 
Daniel, 2006; J. M. Juraska & Rubinow, 2008), which does not reflect the possible interaction of 
hormone treatment with aging. Indeed, studies suggest that the effects of hormone treatment in 
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young female animals are often not the same as the effects of hormone treatment during aging. 
Our laboratory found that young adult females who were ovariectomized and given 17 β-
estradiol (E2) and progesterone were impaired in the acquisition of the Morris water maze 
(Chesler & Juraska, 2000), while replacement of E2 and progesterone in middle aged animals 
facilitated performance of the same task (Markham et al., 2002). Other laboratories have also 
found hormone by age interactions in females within the same study (Foster et al., 2003; 
Talboom, Williams, Baxley, West, & Bimonte-Nelson, 2008). Therefore, it is important to assess 
the effects of hormone treatment in middle aged or aged female animals, a model that more 
closely mimics hormone treatment during human menopause. Recently, studies have used 
middle aged or aged female animals when evaluating the cognitive effects of various types of 
hormone treatment. These studies have found improved performance after E2 treatment on the 
radial arm maze, spontaneous alternation, and both delayed matching to position and delayed 
non-matching to position tasks (Gibbs, 2000; Heikkinen et al., 2004; Markowska & Savonenko, 
2002; M. M. Miller et al., 1999). E2 or estradiol benzoate treatment in both middle aged and aged 
female rodents often improves performance on the Morris water maze (Frick et al., 2002; Frye et 
al., 2005; Harburger et al., 2007; Markham et al., 2002). However, Foster et al., (2003) found no 
effect of estradiol benzoate on acquisition of the water maze in aged animals. Also, 5 weeks of 
oral E2 administration in middle aged animals resulted in impairment on the radial arm maze 
(Fernandez & Frick, 2004). In addition, in aged animals, chronic E2 had no effect on working 
memory errors in the radial arm maze (Gresack & Frick, 2006). The inconsistencies in the 
literature could be due to several factors including the mode of administration (chronic or cyclic 
replacement), pharmacokinetics of the route of administration, whether or not estrogens are 
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combined with a progestogen, and the type of task that is used to assess the influence of hormone 
treatment on cognition. 
The present study was designed to evaluate the effects of different modes of hormone treatment 
(chronic and cyclic) and different regimens of hormone treatment on a reference memory task 
that is hippocampal-dependent, the spatial Morris water maze. Middle aged female rats were 
ovariectomized, immediately given hormone treatment for 6 months, and subsequently tested on 
the Morris water maze. Because much of the animal research to this point has used E2 rather than 
conjugated equine estrogen, we used E2 in order to more directly compare our results. Four types 
of treatment were administered: chronic E2 alone, chronic E2 and progesterone, chronic E2 and 
MPA and cyclic E2 alone. Directly comparing the groups with progesterone to those with MPA 
should help determine if these progestogens differ in preventing the cognitive decline associated 
with aging. Comparing these hormone treatments with E2 only treatments will indicate if the 
addition of a progestogen impacts the outcome of hormone treatments on age related cognitive 
decline. We predicted that middle aged females receiving hormone treatment would perform 
better than animals not receiving hormones. Furthermore, we hypothesized that cyclic E2 
treatment, which is closer to the natural cycle, would be more beneficial for this task than 
chronic E2 treatment. 
Methods 
Subjects 
With the exception of the number of subjects, these procedures were used for all chapters 
regarding hormone treatment. Subjects were 47 female Long Evans hooded rats purchased from 
Charles River Laboratories as retired breeders at the age of 10–12 months. Due to the large 
number of subjects and groups, animals were run in two experimental cohorts. Animals from the 
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same group were pair- or, if necessary, triple housed, in clear Plexiglass cages in a temperature-
controlled environment on a 12:12-hr light–dark cycle. Food and water were available ad libitum 
to all animals, except during the delayed T-maze task discussed in Chapter 2 during which the 
animals were maintained at 85–90% of their normal body weight. Prior to being tested on the 
water maze, food was made available ad libitum for 2 weeks and animals returned to their 
normal body weight. 
All rats were handled once a week and checked for health problems (tumors). Body weight was 
recorded weekly and uterine weight was measured after sacrifice. Animal care and experimental 
procedures were in accordance with National Institutes of Health guidelines and were approved 
by the Institutional Animal Care and Use Committee.  
Hormone treatment 
For this chapter and all chapters regarding hormone replacement the following methods were 
used for hormone treatment. At 12–13 months, all subjects were anesthetized (4% isoflurane) 
and ovariectomized (OVX) via bilateral incisions. In accordance with animal care policy, 
animals were administered the analgesic, carprofen (0.05 mg/kg delivered intraperitoneally) prior 
to surgery and again 12 hours later. Following surgery, subjects were housed individually for 
5 days to allow for recovery and then returned to pair- or triple-housed conditions. Hormone 
administration was initiated immediately after surgery. Animals were randomly assigned into the 
following five groups for the first cohort: no replacement (NR) (n = 3), chronic 17 β-estradiol 
(E2) (n = 4), E2 and MPA (E2 + MPA) (n = 2), E2 and progesterone (E2 + P) (n = 4) or cyclic E2 
(CYE2) (n = 2) and for the second cohort: no replacement (NR) (n = 8), chronic 17 β-estradiol 
(E2) (n = 6), E2 and MPA (E2 + MPA) (n = 8), E and progesterone (E2 + P) (n = 2) or cyclic E2 
(CYE2) (n = 8). 
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17 β-estradiol (E2) administration 
All groups receiving hormones were given E2 in their drinking water. Previous work from our 
lab has found that middle aged, acyclic intact females have circulating estrogen levels averaging 
25–30 pg/ml (Markham & Juraska, 2002; Warren & Juraska, 2000). In a pilot study, we found 
that an E2 dose of 70 µg/kg/day produced estrogen levels averaging 46 pg/ml. In order to keep 
the dose relatively low and in the physiological range for this age group we decreased the dose to 
47 µg/kg/day. E2 was first dissolved in 95% ethanol (2 mg/ml) and then dissolved in water as 
described in Gordon et al. (1986). Water consumption was checked weekly for each cage and 
remained between 60 and 80 ml/kg/day for each rat throughout the experiment for all groups. 
The dose of E2 was calculated by taking the amount of water consumed by a cage and dividing 
by the sum of the weights in that cage. This value was then multiplied by the E2 concentration in 
the water. 
Chronic hormone treatment 
The three chronic hormone treatment groups had E2 in their drinking water every day: E2, E2 + P, 
and E2 + MPA. On the day of OVX, one hormone pellet of either P or MPA was inserted in the 
appropriate groups through a small incision in the nape of the neck. The progesterone pellets 
were made from silastic tubing (Dow Corning) packed with crystalline hormone. Plugs were 
made using short wooden applicator sticks and the implants were sealed with silicone sealant, 
type A (Dow Corning). Studies have shown that 40 mm implants produce hormone levels 
approximating the peak circulating levels of progesterone achieved during the normal estrous 
cycle in the adult female rat (Hope, Bruns, & Thomas, 1992; M. S. Smith, Freeman, & Neill, 
1975). The MPA pellets (1.5 mg) were purchased from Innovative Research of America. Using 
1.5 mg 90 day release pellets results in a dose similar to those in women taking 2.5 mg per day 
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when expected daily release and average weight are factored in. Average weight for animals 
(.4 kg) was calculated at the start of the experiment and the average weight used for humans was 
60 kg. Using these values the expected dose of MPA would be 41.7 micrograms/kg in rat and 
41.6 micrograms/kg in humans. Both the progesterone and MPA pellets were replaced every 
90 days. At the time of pellet replacement, all other groups received a sham surgery. 
Cyclic hormone treatment 
The group with cyclic E2 treatment received E2 in their drinking water three out of every 4 days. 
On the fourth day, the water did not contain E2 and on the following day, the 4-day cycle was 
repeated. Due to a circadian drinking pattern, the highest elevation of estrogen levels occurs 
during peak nocturnal drinking periods and levels return to near baseline fifteen hours later 
(Gordon et al., 1986). Thus, it is likely that on the fourth day, when the animals were not 
receiving any E2, levels of estrogen were not detectable. 
Behavioral procedures 
The first day of testing occurred after approximately 6 months of hormone treatment, so that 
subjects were 18–19 months old at the start of testing. Hormone treatment continued throughout 
the testing period. 
Pretraining 
Apparatus 
The maze used during pretraining was a small wading pool (122 cm in diameter, 36 cm deep), 
located in a room other than the one used for testing. It had a sheet metal liner inserted to provide 
a vertical perimeter, and the visible escape platform (19 cm tall, 9 cm in diameter) was placed in 
the center of the pool. The pool was filled to 1 cm below the surface of the escape platform. The 
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temperature of the water was maintained at 26 °C ± 0.5 °C. The experimenter remained at one of 
four start locations around the pool for all pretraining trials. 
Procedure 
Pretraining began 2 days prior to the first day of testing. Subjects received four consecutive 
pretraining trials, each beginning from one of four start locations. Order of the start location was 
the same for all subjects. Rats were placed in the water while facing the edge of the pool and 
allowed 60 s to find the escape platform. If the platform was not located at the end of 60 s, the 
animal was guided to the platform by the experimenter. The subject remained on the platform for 
15 s and was then removed from the maze and dried off using a towel. After completion of 
pretraining, rats were returned to their home cages. 
Testing 
Apparatus 
The circular water maze testing tank (175 cm in diameter and 74 cm deep) was located in a room 
different than the one used for pretraining. A variety of extra-maze cues were present in the 
testing room. The maze was filled to a depth of 60 cm, 2 cm higher than the escape platform 
(58 cm tall and 10 square cm). White nontoxic paint was used to turn the water opaque, and the 
water was maintained at a temperature of 26 °C ± 0.5 °C. 
Procedure 
Subjects were tested across 4 days, with four trials per day (16 trials total). The location of the 
escape platform remained the same throughout the experiment. At the start of each trial, the 
subject was placed in the water, facing the edge of the tank, from one of four start locations. Start 
location order was the same for all animals. For each trial, the rat was given 60 s to find the 
platform, and the time to reach the platform was recorded. If the subject was unable to locate the 
18 
 
platform by the time 60 s had elapsed, the experimenter guided the subject to the platform. The 
subject remained on the platform for 15 s before being removed from the maze and dried off 
using a towel. The intertrial interval varied between 13 and 15 min. At the end of testing on Day 
4, the platform was removed and a probe trial lasting 60 s was performed on the second cohort of 
animals. A video camera was mounted above the center of the tank and all trials were recorded. 
The experimenter recorded latency times with a stopwatch. After testing was complete, the 
pathlengths taken by the subjects to reach the platform were traced and then scanned into a 
computer and pathlengths were calculated using Image J (National Institutes of Health). Swim 
speed was calculated by dividing pathlength by latency. 
Statistical analysis 
Body weights and uterine weights were analyzed using a two-way ANOVA (5 Treatment × 2 
Cohort). Pretraining latency was analyzed using a two-way (5 Treatment × 4 Trial) ANOVA 
with repeated measures on trial. For testing, latency and pathlength data were analyzed with each 
cohort of animals as a factor using a three-way (5 Treatment × 2 Cohort × 4 Day) ANOVA with 
repeated measures on day. Since there were no main effects of cohort and no cohort by treatment 
interaction, the two cohorts were then combined for analysis using a two-way (5 Treatment × 4 
Day) ANOVA with repeated measures on day. Furthermore, post-hoc t-tests of treatment at each 
of the 4 days of testing were performed for both latency and pathlength because we expected 
differences between hormone groups in the later trials (Warren & Juraska, 2000). In addition, 
each day of testing was divided into two blocks of two trials for analysis because previous work 
in our lab indicated that differences in water maze performance may be due to the animals 
forgetting the task after a one-hour delay or overnight (Markham et al., 2002; Warren & Juraska, 
1997). Therefore preplanned comparisons of Block 2 versus 3, 4 versus 5, and 6 versus 7 were 
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performed to compare performance at the beginning of each day with performance at the end of 
the previous day and determine whether animals forgot the task overnight. At the request of a 
reviewer, linear trend analyses were conducted to investigate whether the rate of improvement 
over trials differed between the groups. Swim speed during testing was analyzed using a two-
way ANOVA (5 Treatment × 4 Day). Time spent in the target quadrant during the first half of 
the probe trial (30 s) and during the entire probe trial (60 s) was analyzed separately using a one-
way ANOVA. Two-tailed t-tests were used for all post-hoc comparisons. 
Results 
Body weight and Uterine weight 
There was a significant effect of treatment on body weight (F (4, 41) = 4.258, p < 0.007). Post-
hoc t-tests revealed that the no replacement group weighed significantly more than all groups 
that received hormone treatment except the group receiving cyclic E2 treatment for which there 
was a non-significant trend. (E2: p < 0.01; E2 + MPA: p < 0.003; E2 + P: p < 0.001; CYE2: 
p < 0.08). No other comparisons reached significance. 
There was a significant effect of treatment (F (4, 36) = 4.149, p < 0.01) and cohort (F 1, 
36) = 11.169, p < 0.01) on uterine weight but there was no treatment × cohort interaction (F 4, 
36) = 0.597, p = 0.667). Post-hoc t-tests revealed that uterine weight in the no replacement group 
was significantly less than all groups that received hormone treatment except the group receiving 
chronic E2 and progesterone treatment for which there was a trend. (E2: p < 0.01; E2 + MPA: 
p < 0.01; CYE2: p < 0.01; E2 + P: p < 0.058;), indicating that hormone treatment was 
physiologically effective (Table 1) 
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Pretraining 
There was no significant effect of treatment on pretraining performance nor was there an 
interaction between treatment and pretraining trials (Figure 1). 
Latency 
There was a significant effect of day (F (3, 126) = 58.954, p < 0.001) as latency decreased as the 
animals became skilled at the water maze task. There was also a main effect of treatment (F (4, 
42) = 2.683, p < 0.05). The treatment by day interaction was not significant. Post-hoc t-tests 
revealed that the chronic E2 and MPA group performed significantly worse than all other groups 
receiving hormone treatment (E2: p < 0.007; E2 + P: p < 0.03; CYE2: p < 0.03), but they were not 
significantly different from the no replacement group (Figure 2A). No hormone treated group 
was significantly different than the no replacement group. Analysis by 2-trial block indicated that 
none of the groups forgot the task overnight. At the suggestion of a reviewer we conducted a 
linear trend analysis of block to determine whether the rate of improvement over trials differed 
between the treatment groups. All groups improved performance across training as seen with the 
significant linear trend for block (F(1, 42) = 181.427, p < 0.001), but treatment groups did not 
differ in their rates of improvement. 
Furthermore, preplanned comparisons of treatment at each of the 4 days of testing found that the 
animals receiving chronic E2 had significantly shorter latencies than no replacement (p < 0.05) 
and cyclic E2 (p < 0.02) treated animals on the last day of testing (Figure 3A). Importantly, there 
were no differences between any of the groups on the first day of testing.  
Pathlength 
Differences in pathlength were very similar to those found for latency. There was a significant 
effect of day on pathlength (F (3, 126) = 57.715, p < 0.001) such that pathlength became shorter 
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as testing progressed. There was also a main effect of treatment (F (4, 42) = 4.198, p < 0.007). 
The treatment by day interaction was not significant. Post-hoc t-tests revealed that the chronic E2 
and MPA group had significantly longer pathlengths than all other groups receiving hormone 
treatment (E2: p < 0.008; E2 + P: p < 0.04; CYE2: p < 0.004), but they were not significantly 
different from the no replacement group (Figure 2B). No hormone treated group was 
significantly different than the no replacement group. Analysis by 2-trial block indicated that 
none of the groups forgot the task overnight except for E2 + MPA between blocks 6 and 7 
(p < 0.04). Similar to latency, all groups improved performance across training as seen with the 
significant linear trend for block (F(1, 42) = 137.055, p < 0.001), but treatment groups did not 
differ in their rates of improvement. 
Furthermore, preplanned comparisons of treatment at each of the 4 days of testing found that on 
the last day of testing, the chronic E2-treated animals had significantly shorter pathlengths than 
the cyclic E2-treated animals (p < 0.05) and a trend in comparison to no replacement animals 
(p < 0.09) (Figure 3B). There were no differences between any of the groups on the first day of 
testing. 
Swim speed 
Swim speed decreased across the 4 days of training (F(3, 126) = 4.668, p < 0.01). There was no 
effect of treatment on swim speed, as well as no treatment by day interaction. 
Probe trial 
 
Treatment did not significantly influence the amount of time spent in the target quadrant during 
the full 60 s or during the first 30 s of the probe trial (Figure 4).  
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Discussion 
The present study found that in middle aged female rats, long-term administration of chronic E2 
with MPA resulted in worse performance on the Morris water maze than all other types of 
hormone treatment but not the group with no replacement. Also by the fourth (and last) day of 
training, chronic E2 treatment improved performance on the maze, but this effect was not seen 
earlier in training nor was it seen in the cyclic E2 group. It should be noted that hormone 
treatment did not alter swim speed and there were no differences in pretraining latencies which 
suggests no motivational differences between groups. 
The most striking finding is that middle aged rats receiving E2 in combination with MPA, while 
not different than no replacement, performed significantly worse on the Morris water maze than 
all other groups receiving hormone treatment. To our knowledge, no published studies have 
investigated the effects of E2 in combination with MPA, the most common progestin given to 
women, on cognition in an aging animal model. However, a recent study found that MPA 
administered without estrogen impaired performance on the water radial arm maze and the 
spatial water maze (Braden et al., 2010). In addition, the Women’s Health Initiative found that 
conjugated equine estrogen in combination with MPA increased the number of subjects 
diagnosed with either probable dementia or mild cognitive impairment in post menopausal 
women (Espeland et al., 2004; S. R. Rapp et al., 2003; Shumaker et al., 2003; Shumaker et al., 
2004). Although the dose of MPA was calculated to be similar to that in humans, the route of 
administration in humans is oral, while the route used in this study was subcutaneous. As 
previously noted, routes of administration alter rates of metabolism and therefore future studies 
need to assay levels of MPA in similarly treated animals of the same age. 
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The known neural effects of MPA are mixed. In vitro studies have found that E2 protected 
against glutamate toxicity while E2 in combination with MPA did not (Nilsen, Morales, & 
Brinton, 2006). In addition, progesterone protected against kainic acid-induced neuronal loss 
while MPA failed to do so (Ciriza et al., 2006). However, in male brain-injured rats, MPA 
resulted in a reduction of cerebral edema (Wright, Hoffman, Virmani, & Stein, 2008). Also, 
chronic treatment with conjugated equine estrogen alone or in combination with MPA resulted in 
an increase in the number of synapses in the hippocampus in young female rats (Silva, Mello, 
Freymuller, Haidar, & Baracat, 2000). At present, too little is known about long-term neural 
effects of hormone treatments during normal aging to predict behavioral outcomes. Furthermore, 
this task is a measure of spatial reference memory and it is possible that the outcome would be 
different in other tasks that depend on other types of memory (e.g., working, nonspatial), and this 
should thus be further evaluated. 
Our finding that E2 improved water maze performance on the fourth day of testing is consistent 
with previous work from our lab and others showing that chronic treatment with E2 or estradiol 
benzoate benefited acquisition and retention of the water maze in middle age female rats (Foster 
et al., 2003; Markham et al., 2002; Talboom et al., 2008). Although we did not see significant 
differences on our probe trial, it is possible that the trends seen would have been significant with 
a larger sample size. Studies have also found that chronic E2 treatment in middle aged OVX rats 
enhanced performance on the several other tasks including, the T-maze (Gibbs, 2000), object 
recognition (Vaucher et al., 2002), and spontaneous alternation (M. M. Miller et al., 1999). 
However, not all studies in middle aged animals have found beneficial effects of hormone 
treatment (Fernandez & Frick, 2004; Gresack & Frick, 2006). Since there is increasing evidence 
that hormone treatment may not be beneficial if initiated after long-term deprivation of hormones 
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all studies discussed previously initiated hormone treatment within 1 month of ovariectomy. 
Although, the length of hormone deprivation fails to explain the differing results of the previous 
studies, other variables to consider include the route of administration, the type of task used, and 
species and strain differences. In addition, a recent study found that reproductive experience 
alters responsiveness to estrogens (Barha & Galea, 2009), and it is possible that the use of retired 
breeders in the present study influenced our results. Furthermore, animals in the present study 
were exposed to a behavioral experiment prior to the present one which could have influenced 
performance. 
The oral route of administration was used here to model the most common route of 
administration of hormone replacement in post menopausal women. In rodents, E2 in the 
drinking water has been shown to produce levels that fluctuate throughout the day with the 
highest levels two hours after the onset of the dark cycle and then falling back to baseline during 
the following light cycle (Gordon et al., 1986). The only other study to use this route of 
administration found improved performance on object recognition but impaired reference 
memory on a water-escape motivated 8-arm radial arm maze (Fernandez & Frick, 2004). In 
contrast, another study from the same lab found that daily injections of E2 did not improve 
performance on object recognition (Gresack & Frick, 2006). A possible explanation for the 
differing results is that the stress of injections may have interfered with the ability of E2 to 
improve performance on object recognition. Chronic oral administration of hormones removes 
the stress associated with daily injections, thereby decreasing the possibility of an interaction of 
hormones and stress on the behavioral outcome. Furthermore, the oral route allows for first pass 
metabolism of the hormone which may affect the outcome of the treatment. Although we were 
not able to measure blood levels of estrogen, the group differences in body weights and uterine 
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weights indicate that the treatment was physiologically effective. Future studies should assay 
levels of estradiol (and MPA) in these treated groups. It should be noted that because estrogen 
was dissolved in ethanol, the hormone treated groups were exposed to a small amount of ethanol 
(0.014 g/kg/day) in their drinking water, while the no replacement animals were not. However, a 
previous study found no effect on the water maze when adult rats were exposed to 0.5 g/kg of 
ethanol, and ethanol levels of 2.0 g/kg were required for impairments on water maze 
performance in adult animals (Acheson, Ross, & Swartzwelder, 2001). 
Unlike chronic E2 treatment, there were no indications that cyclic E2 treatment benefited 
performance on the Morris water maze. On the fourth day of testing, the chronically treated E2 
group performed significantly better than the animals treated cyclically. Animals in the cyclic E2 
group were on the third day of their 4-day cycle of hormone treatment and thus received E2 on 
this day of testing. The studies that have investigated the effects of repeated cyclic hormone 
treatment are inconsistent. Weekly injections of E2 plus progesterone enhanced performance of 
aged female rats on a delayed match-to-position T-maze task (Gibbs, 2000) and in aged rhesus 
monkeys, cyclic estradiol cypionate injections improved spatial working memory performance 
(P. R. Rapp et al., 2003). Two other studies have found that both continuous and intermittent E2 
significantly improved task acquisition in middle aged and aged animals (Bimonte-Nelson et al., 
2006; Markowska & Savonenko, 2002). However, cyclic administration of estradiol benzoate did 
not improve performance in middle-aged female rats on a 12-arm radial arm maze (Ziegler & 
Gallagher, 2005). Furthermore, while continuous E2 treatment had no effect on spatial working 
or reference memory in the radial arm maze, intermittent E2 treatment impaired spatial reference 
memory (Gresack & Frick, 2006). Although the results of these studies differ, none of the studies 
found that cyclic treatment of hormones was more beneficial for task performance than chronic 
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treatment. It is important to note that most of the studies that have attempted to mimic the natural 
cycle of hormones have only simulated certain aspects of the cycle, so that the inconsistent 
results are not surprising. For example, estrogen cyclicity was mimicked in the current study, but 
not the fluctuation in progesterone levels. It is possible that more closely simulating the natural 
cycle by including fluctuations in both estrogen and progesterone levels may be more beneficial 
than the chronic treatment of ovarian hormones. 
While E2 in combination with progesterone did not benefit this task, it did not impair 
performance as did E2 in combination with MPA. The few studies that have administered 
estrogens in combination with progesterone have resulted in equivocal findings. Some studies 
have found beneficial effects of estrogens given with progesterone. Gibbs (2000) found that 
weekly injections of E2 in combination with progesterone improved T maze performance in aged 
rats. Furthermore, in middle aged rats, E2 plus progesterone enhanced performance on the Morris 
water maze as well as E2 alone (Markham et al., 2002). In contrast, another study found that 
progesterone reversed the beneficial effects of estradiol on this same task in middle aged rats 
(Bimonte-Nelson et al., 2006). However, similar to the present study, Bimonte-Nelson et al. 
(2006) found that while long-term treatment with estradiol and progesterone does not benefit the 
water maze, animals receiving this combination are not impaired on the task when compared to 
those not receiving hormone treatment. 
Performance on the Morris water maze is dependant to a large degree on the hippocampus 
(Redish & Touretzky, 1998). Several studies have reported that estrogens influence the 
morphology and functional connectivity of the hippocampus in young adult females (Warren, 
Humphreys, Juraska, & Greenough, 1995; Woolley & McEwen, 1992; Woolley, Weiland, 
McEwen, & Schwartzkroin, 1997). However, E2 treatment does not increase spines in aged 
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animals (Adams, Shah, Janssen, & Morrison, 2001). Interestingly, chronic MPA exposure results 
in an increase in synapses in the hippocampus of young animals (Silva et al., 2000), although it is 
not known if this occurs in aged animals. The neural mechanisms underlying the behavioral 
effects of hormone treatment may be different in young and aged animals. In future studies it 
will be imperative to examine the neural effects of MPA, the progestin most commonly 
prescribed to menopausal women, in an aging female model. 
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Figures and Tables 
 
Figure 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Mean latency to find the visible platform during four trials of pretraining. There were 
no significant differences between groups. 
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Figure 2. Mean ± SEM latency (A) and pathlength (B) to find the submerged platform averaged 
across four days of testing for all groups. The E + MPA group had significantly longer latencies 
(E: p < .01; E + P: p < .03; CYE: p < .03) and pathlengths (E: p < .01; E + P: p < .04; CYE: p < 
.01) than all other groups receiving hormone replacement. 
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Figure 3. Mean ± SEM latency (A) and pathlength (B) to find the submerged platform for each 
of the four days of testing for all groups. The group receiving chronic 17 β-estradiol performed 
better on Day 4 than both NR and CYE groups. * (p < .05); # indicates a trend (p < .09). 
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Figure 4. 
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Figure 4. Mean ± SEM time spent in the target quadrant during the first thirty seconds of the 
probe trial for all groups. There were no significant differences between groups 
 
 
Table 1.  Body and Uterine Weight 
Hormone Group Mean Body Weight (g) Mean Uterine Weight (g) 
No replacement 584.5 ± 20.6 .1 ±.01 
Chronic E2 498.2 ± 22.2* .17 ±.01* 
Chronic E2 & P 479 ± 32.4* .15 ± .02# 
Chronic E2 & MPA 466.8 ± 27.6* .17 ± .02* 
Cyclic E2 526.6 ± 23.4# .16 ± .01* 
 
Body and uterine weights were taken at sacrifice for all groups. No replacement animals weighed 
significantly more and had lower uterine weights that all hormone treated groups. * p <.01   
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CHAPTER 2  
LONG-TERM REPLACEMENT OF ESTROGEN IN COMBINATION WITH 
MEDROXYPROGESTERONE ACETATE IMPROVES ACQUISITION OF AN 
ALTERNATION TASK IN MIDDLE AGED FEMALE RATS. 2 
                                                          
2
 Previously published as: Chisholm NC, Juraska JM. Long term replacement of estrogen in 
combination with medroxyprogesterone acetate improves acquisition of an alternation task in 
middle aged female rats. Behav Neurosci. 2012 Feb;126(1):128-36 
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Abstract 
Studies have shown that ovarian hormones protect against some of the cognitive deficits 
associated with aging. Although much of the literature in rodents has focused on hippocampal 
dependent tasks, studies suggest that tasks dependent on the prefrontal cortex are also influenced 
by ovarian hormones. The present study investigated the effects of ovarian hormone treatment 
during aging on a delayed alternation t-maze. Female Long Evans hooded rats were 
ovariectomized at middle age (11-12 months) and placed in one of 5 treatment groups: no 
replacement, chronic estradiol (E2), cyclic E2, chronic E2 and progesterone, or chronic E2 and 
medroxyprogesterone acetate (MPA). Following six months of hormone treatment, animals were 
trained to alternate in a t-maze. After reaching criterion, a series of delays from 5 to 90 seconds 
were introduced in random order. Rats receiving E2 with MPA reached criterion significantly 
faster than animals not receiving treatment and those who received chronic or cyclic E2 only. 
There was a nonsignificant trend for animals receiving E2 and progesterone to reach criterion in 
fewer sessions than animals receiving E2 only.  Mode of administration, cyclic or chronic, did not 
affect performance. Hormones did not affect performance on the delayed alternation. This study, 
in combination with previous research, indicates that hormone effects cannot be generalized 
across tasks, age or duration, and long-term estrogen in combination with MPA can be beneficial 
for some tasks. 
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Introduction 
In humans, several studies have identified the prefrontal cortex (PFC) as a region that has greater 
decline in gray matter volume during aging than other brain areas (Raz et al., 2005; Resnick et 
al., 2003).  Also, the largest decline in metabolism during aging is localized to the medial 
prefrontal cortex (Pardo et al., 2007) and decreases in synaptic density, spine density, and 
dendritic arborization have been found in the aged human frontal cortex (de Brabander et al., 
1998; Huttenlocher, 1979; Jacobs et al., 1997; Masliah, Mallory, Hansen, DeTeresa, & Terry, 
1993). In addition to the anatomical changes, several studies have shown that the functions of the 
PFC, including behavioral flexibility, attention, memory, and language, are impaired during 
aging (reviewed in Stuss & Benson, 1984). For example, the aged have deficits in item 
recognition and source memory as well as delayed verbal recall (Wegesin & Stern, 2007). In 
addition, older adults performed worse on the Wisconsin card sorting task, a test of executive 
functioning, and on a free-recall task which was mediated more by executive functioning 
impairments than deficits in perceptual speed (Baudouin, Clarys, Vanneste, & Isingrini, 2009).  
The rat medial prefrontal cortex (mPFC) also experiences age-related changes. For example, 
reductions in both spine density and arborization of dendrites have been found in the mPFC of 
aged animals (Grill & Riddle, 2002; Markham & Juraska, 2002; Wallace et al., 2007) and the 
density of axospinous synapses decreases with age (Nakamura, Kobayashi, Ohashi, & Ando, 
1999). Age-related changes also occur in the levels and turnover of dopamine and its metabolites 
(Godefroy, Bassant, Lamour, & Weil-Fugazza, 1991) as well as decreases in the amount of  
dopaminergic innervations (Mizoguchi et al., 2009), and  NMDA receptor density (Castorina, 
Ambrosini, Pacific, Ramacci, & Angelucci, 1994; Magnusson & Cotman, 1993; Miyoshi, Kito, 
Doudou, & Nomoto, 1990). Similar to humans, the mPFC in rodents plays a role in many 
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cognitive abilities, including behavioral flexibility and memory for temporal order (Birrell & 
Brown, 2000; De Bruin et al., 2000; Kolb, 1990) and these measures are impaired during aging. 
For example, aged rats showed decreased performance, as compared to young rats, on an object 
recognition task (Wallace et al., 2007) and attentional set shifting (Barense, Fox, & Baxter, 
2002). Also, studies have found deficits in aged animals when tested on delayed alternation tasks 
using the t-maze (Ando & Ohashi, 1991; Mizoguchi et al., 2009) and operant versions (Neese, 
Korol, Katzenellenbogen, & Schantz, 2010).  
In both humans and rodents, several studies have shown that the presence of ovarian hormones 
may protect against some of these behavioral deficits. Although much of the literature has 
focused on hippocampal dependent tasks, ovarian hormones during aging also influence tasks 
dependent on the prefrontal cortex. In postmenopausal women, performance on a tasks relying 
on the prefrontal cortex, including digit ordering, delayed recall and a Wisconsin card sorting 
task, was improved after both short- term and long-term estrogen treatment (Krug et al., 2006; 
Wegesin & Stern, 2007). In addition, long-term estrogen only and estrogen and progestogen 
treatments enhance measures of verbal memory and improves performance on tasks of spatial 
and verbal working memory (Carlson & Sherwin, 1998; Duff & Hampson, 2000; Kampen & 
Sherwin, 1994). In rodents, chronic estradiol administered via injections and silastic capsules 
improves performance on a delayed-nonmatching-to-position task (Markowska & Savonenko, 
2002; M. M. Miller et al., 1999) and long-term chronic estradiol alone or in combination with 
progesterone improves performance on a delayed-matching-to-position task (Gibbs, 2000). 
However, the Women’s Health Initiative found that conjugated equine estrogen alone or 
administered with medroxyprogesterone acetate (MPA), the most common progestin given to 
women, failed to enhance cognition and increased the number of subjects diagnosed with either 
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probable dementia or mild cognitive impairment in post menopausal women (Espeland et al., 
2004; S. R. Rapp et al., 2003; Shumaker et al., 2003; Shumaker et al., 2004). However, hormone 
treatment in the Women’s Health Initiative was started several years after the onset of 
menopause and a recent review of the existing literature found hormone treatment to be 
beneficial when initiated close to the onset of menopause but not when initiated later (Rocca, 
Grossardt, & Shuster, 2011). 
MPA is a synthetic analogue of progesterone and binds to progesterone receptors, as well as 
androgen and glucocorticoid receptors (Bamberger et al., 1999; Bardin et al., 1983).  However, 
progesterone is readily metabolized to allopregnanolone (Majewska, Harrison, Schwartz, Barker, 
& Paul, 1986) and MPA inhibits the enzymes needed for this conversion (Jarrell, 1984; Lee, 
Miller, & Auchus, 1999; Penning, Sharp, & Krieger, 1985). Differences in mechanisms of action 
between these progestogens may result in divergent behavioral responses. Surprisingly, few 
studies have addressed the effects of MPA on cognition. Our lab has previously shown that long-
term treatment with estrogen in combination with MPA attenuates the beneficial effects of 
estrogen alone or estrogen in combination with progesterone on water maze performance in 
middle aged rats (Lowry, Pardon, Yates, & Juraska, 2010).  In addition, MPA administered 
without estrogen impaired performance on the water radial arm maze and the spatial water maze 
(Braden et al., 2010). When these two studies directly compared the behavioral effects of MPA 
with those of progesterone, they both found that progesterone did not impair performance on the 
water maze, but progesterone and MPA both impaired performance on the water radial arm maze 
(Braden et al., 2010; Lowry et al., 2010). Both of these studies used hippocampal dependant 
tasks and it is unknown how MPA would affect performance on tasks that are mediated by the 
mPFC. 
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Because tasks that are mediated by the mPFC are impaired during aging and because studies 
suggest that the presence of estrogen may prevent this, we chose to evaluate the effects of 
hormone treatment, including MPA, on age-related cognitive decline in the t-maze, a working 
memory task dependent on the mPFC. Middle aged female rats were ovariectomized, given 
ovarian hormone treatment, and subsequently tested on an alternation and delayed alternation 
task. We administered four different types of replacement: chronic replacement of estrogen 
alone, chronic replacement of estrogen and progesterone, chronic replacement of estrogen and 
MPA, or cyclic replacement of estrogen alone. Differences between groups of animals may 
suggest distinct roles for estrogen and progestogens during aging, and would indicate whether 
the effects vary with the type of progestogen administered. Whether treatment with estrogen in 
combination with MPA or progesterone will differentially affect performance on learned 
alternation or delayed alternation during aging is currently unknown.  
Methods 
Subjects 
Subjects were 51 female Long Evans hooded rats purchased from Charles River Laboratories as 
retired breeders at the age of 11-12 months. Due to the large number of subjects and limited 
availability from the supplier, animals were run in three experimental cohorts. Animals from the 
same group were pair- or, if necessary, triple housed, in clear Plexiglass cages in a temperature-
controlled environment on a 12:12-hr light–dark cycle. Food and water were available ad libitum 
to all animals, except during behavioral procedures during which the animals were maintained at 
85-90% of their normal body weight.  All rats were handled, weighed, and checked for health 
problems (tumors) once a week. At sacrifice, both body and uterine weights were measured. 
Animals from two of the cohorts were used in another behavioral experiment following 
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completion of the present task (Lowry et al., 2010).  Animal care and experimental procedures 
were in accordance with National Institutes of Health guidelines and were approved by the 
Institutional Animal Care and Use Committee. 
Hormone Treatment 
The ovaries were removed from all subjects at 12-13 months.  Subjects were anesthetized with 
4% isoflurane and ovariectomized via bilateral incisions. Animals were administered the 
analgesic, carprofen (0.05 mg/kg delivered intraperitoneally), prior to surgery and again 12 hours 
later, in accordance with animal care policy. Subjects were housed individually for five days 
following surgery to allow for recovery and then returned to pair- or triple-housed conditions. 
Hormone administration was initiated the day of surgery and continued throughout the 
behavioral procedures. Animals were randomly assigned into the following five groups: no 
replacement (NR) (n = 12), chronic 17 β-estradiol (E2) (n = 11), E2 and MPA (E2 + MPA) (n = 
12), E2 and progesterone (E2 + P) (n = 7) or cyclic E2 (n = 9). 
17 β-estradiol (E2) Administration. As in Lowry et al. (2010), all groups receiving hormones 
were given E2 in their drinking water. Acyclic intact females continue to secrete estrogen at 
levels between 25–30 pg/ml and progesterone at 10-40 ng/ml depending on estropausal state 
(Markham & Juraska, 2002; A. E. Miller & Riegle, 1980; Warren & Juraska, 2000; Wise & 
Ratner, 1980). In a pilot study, we found that middle aged female rats drink a steady amount of 
water whether individually or group housed, and an aqueous E2 dose of 70 µg/kg/day produced 
estrogen levels averaging 46 pg/ml. In order to keep the dose in the physiological range for this 
age group, we decreased the dose to 47 µg/kg/day. E2 was first dissolved in 95% ethanol 
(2mg/ml) and then dissolved in water as described previously (Gordon et al., 1986). Water 
consumption was measured weekly for each cage and remained between 120-140 ml/kg/day 
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throughout the experiment for all groups. The dose of E2 was calculated by taking the amount of 
water consumed by a cage and dividing by the sum of the weights in that cage. This value was 
then multiplied by the E2 concentration in the water. 
Chronic Hormone Treatment. Estradiol was available in the drinking water every day for the 
three chronic hormone treatment groups: E2, E2 + P, and E2 + MPA. On the day of OVX, one 
hormone pellet of either P or MPA was inserted in the appropriate groups through a small 
incision in the nape of the neck. The progesterone pellets were made from silastic tubing (Dow 
Corning) packed with crystalline hormone. Plugs were made using short wooden applicator 
sticks and the implants were sealed with silicone sealant, type A (Dow Corning). Studies have 
shown that 40 mm implants produce hormone levels between those found in aging female rats in 
persistent estrus and persistent diestrus (J. W. Liu, Dawson, Peters, Baker, & Walker, 1997). The 
MPA pellets (1.5mg) were purchased from Innovative Research of America. Using 1.5mg 90 day 
release pellets results in a dose similar to those in women taking 2.5 mg per day when expected 
daily release and average weight are factored in. Progesterone and MPA pellets were replaced 
every 90 days. All other groups received sham surgeries at the time of pellet replacement. 
Cyclic Hormone Treatment.  E2 was administered in the drinking water three out of every four 
days in the group receiving cyclic E2 treatment. On the fourth day, the water did not contain E2 
and on the following day, the four day cycle was repeated. Due to a circadian drinking pattern, 
the highest elevation of estrogen levels occurs during peak nocturnal drinking periods and levels 
return to near baseline fifteen hours later (Gordon et al., 1986) which indicates that a day without 
E2 resulted in levels near baseline.  
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Behavioral Procedures 
The first day of testing occurred after approximately five months of hormone treatment, so that 
subjects were 17-18 months old at the start of testing.  Hormone treatment continued throughout 
the testing period and all pellets were at approximately 55 days into their 90 day period. Food 
deprivation began five days prior to introduction to the maze. Animals were food deprived to 85-
90% of their free feeding body weight.  
Apparatus 
The t-maze consisted of an approach alley (15 cm wide X 45 cm long) and two goal arms (15 cm 
wide X 45 cm long). The start box (15 cm wide and 26 cm long) opened into the approach alley.  
The walls of the maze were 15 cm high and were constructed of black plexiglass. Manually 
operated sliding doors were positioned at the entrance to each goal arm. The orientation and 
position of the maze were not changed during the experiment. 
Testing Procedure 
A previous study in our lab ran adolescent animals twice a day in order to complete testing 
within the adolescent time period (Koss, Franklin, & Juraska, 2011). We used the same 
procedure as that study; therefore in the present study, animals completed two sessions per day 
during all phases of the task. 
Habituation.  Animals were exposed to the maze during four 10-minute sessions over 2 days. 
During this time, each arm was baited with sunflower seeds and animals were allowed to roam 
the maze freely for 10 minutes.   
Forced Alternation. Animals were placed in the maze for 10 forced alternation trials twice per 
day for three days for a total of 6 sessions.  During each trial, the animal had access to only one 
open arm, which was baited with a sunflower seed reward and the opposite arm was blocked. 
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Once the animals had eaten the sunflower seed they were returned to the start box. The arm 
previously visited was then blocked, restricting access during the next run to only the alternate 
arm. For all trials, the animals remained in the chosen arm until they had eaten the sunflower 
seed or until 15 seconds had elapsed.  
Alternation. On the first choice run, animals were placed in the start box and rewarded for 
choosing either arm. During the next 10 trials, animals were rewarded only when they entered 
the alternate arm. Each animal completed two sessions of 11 trials a day (1 free choice trial 
followed by 10 test trials) until a criterion of 80% over three consecutive sessions was achieved.  
Delayed Alternation. All animals that reached criterion were then run for two sessions where 
they were introduced to short delays of 5, 10, and 15 seconds to reduce the level of stress 
associated with delays. Then the delayed alternation portion of the task was introduced.  Delays 
of 5, 10, 15, 30, 60, 90 seconds were presented in a semi-randomized order. The procedures were 
the same as the alternation, except that after a trial, animals were returned to the start box where 
they would experience one of the delays. Each animal completed two sessions of 11 trials a day 
for a total of 15 sessions. This resulted in 25 trials at each delay. If an animal made an incorrect 
choice and then continued to choose the same arm, this was classified as a perseverative error in 
both the no-delay and delayed alternation portions of the task. 
Post-behavior procedures. All animals were returned to ad libitum food.  Two weeks after the 
completion of the present study, two of the three cohorts were run on a spatial water maze that 
has been previously reported (Lowry et al., 2010).  At 19-20 months of age, they were sacrificed 
for neuroanatomical studies and body weight and uterine weights were recorded. Hormone 
treatment continued until sacrifice. 
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Statistical Analysis 
Body weights and uterine weights were analyzed using a one-way ANOVA with cohort as a 
covariate. The number of sessions required to reach criterion was analyzed using a one-way 
ANOVA with cohort as a covariate. Performance on delayed alternation was analyzed using a 
two-way (5 Treatment x 6 Delay) ANOVA with repeated measures on delay and cohort as a 
covariate. Cohort was not significant for any of the analyses. Fisher’s LSD tests were used for all 
post-hoc comparisons.  
Results 
Body Weight 
There was a significant effect of treatment on body weight (F (4, 45) = 6.470, p < .001).  Post-
hoc tests revealed that the no replacement group weighed significantly more than all groups that 
received hormone treatment (E2: p < .001; E2 + MPA: p < .001; E2 + P: p < .01; Cyclic E2: p < 
.02) (Table 2). 
Uterine Weight 
There was a significant effect of treatment (F (4, 45) = 5.902, p < .001) on uterine weight. Post-
hoc tests revealed that uterine weight in the no replacement group was significantly lower than 
all groups that received hormone treatment (E2: p < .001; E2 + P: p < .01; E2 + MPA: p < .001; 
Cyclic E2: p < .03), indicating that hormone treatment was physiologically effective (Table 2).  
Alternation 
A one way ANOVA revealed a main effect of treatment on the number of sessions to reach 
criterion (F(4, 45) =2.731, p  <. 05). Post-hoc Fisher’s LSD revealed that the group receiving E2 
+ MPA required  significantly fewer sessions to reach criterion than animals in three groups: no 
replacement (p < .04), chronic E2 (p < .02), and cyclic E2 (p < .02). There were non-significant 
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trends for animals that received E2 + P to require fewer days to meet criterion than animals 
receiving chronic E2 (p < .09) and cyclic E2 (p < .08) (Figure 5). The groups did not differ in the 
number of perseveration errors during alternation. 
Delayed Alternation 
One animal that had met criterion in the learned alternation task failed to leave the start box 
during the delayed alternation task and was not included in analysis. There was a significant 
effect of delay (F(5, 220) = 3.135 p <.01) (Figure 6) such that increasing the intertrial delay 
significantly reduced performance in all treatment groups. Hormone treatment was not 
significant (F(4, 44) =.959 p =.440), nor was there a significant interaction between treatment 
and delay. The groups did not differ in the number of perseveration errors during delayed 
alternation. 
Cyclic E2   
No effects were found within the cyclic E2 group between days when E2 was administered in the 
drinking water and when it was not. 
Discussion 
Long-term chronic administration of E2 in combination with MPA enhanced acquisition of an 
alternation task in middle aged female rats.  Animals receiving E2 in combination with MPA 
reached criterion in fewer sessions than controls and animals who received chronic or cyclic E2 
only. Performance on delayed alternation decreased as the intertrial delay increased; however, 
hormone treatment failed to alter performance on the delayed portion of the task. These results 
are in contrast to our previous study in which 80% of the animals used in the present study were 
tested on the water maze and estradiol in combination with MPA impaired performance as 
compared to other hormone treated groups (Lowry et al., 2010). 
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Lesions of several different brain regions, including the hippocampus, striatum and prefrontal 
cortex, impair alternation behavior (reviewed in Lalonde, 2002) so that identifying a single brain 
region responsible for the behavioral outcome in this study is difficult. Furthermore, although 
animals can use allocentric spatial relationships to alternate in the t-maze, a study that 
manipulated several aspects of the maze environment found that performance on this task does 
not rely exclusively on these extramaze cues (Dudchenko, 2001). The beneficial effect of E2 in 
combination with MPA found in the present study differs from previous studies examining the 
effects of MPA on cognition. Chronic MPA alone or in combination with E2 impaired 
performance on the water maze in middle aged animals (Braden et al., 2010; Lowry et al., 2010). 
Performance on the water maze relies heavily on the hippocampus, which suggests that MPA 
might impair functioning of this brain region. Although MPA seems to impair hippocampal 
functioning, there is no evidence to suggest that this is true for other brain regions which may 
become engaged while solving the task used in the current study.    
Interestingly, E2 in combination with progesterone resulted in a more variable but similar pattern 
of fewer trials to acquire the alternation task as E2 in combination with MPA. In agreement with 
this finding, weekly injections of E2 in combination with progesterone improved t-maze 
performance in aged rats (Gibbs, 2000). It is unknown if progesterone and MPA have similar 
neural effects because few studies have directly compared them. Braden et al. (2010) found that 
chronic MPA significantly and progesterone marginally decreased levels of glutamic acid 
decarboxylase in the hippocampus when administered via osmotic pumps However, a single 
injection of progesterone transiently down regulated mRNA expression of GABAa subunits, 
where as MPA did not (Pazol, Northcutt, Patisaul, Wallen, & Wilson, 2009).  If MPA and 
progesterone result in different neural outcomes, they may differentially affect cognition. Indeed 
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our previous study found that while long-term E2 in combination with MPA impaired 
performance when compared to other hormone treated groups on the water maze, long-term E2 in 
combination with progesterone did not (Lowry et al., 2010). However, the current study found 
similar effects of the two progestogens, emphasizing the importance of the task used to evaluate 
learning and memory.  
The t-maze task used in the present study requires the animal to recall information that varies 
from trial to trial and therefore tests working memory (Markowska, Olton, & Givens, 1995). This 
study is the first to examine the effects of long-term treatment of E2 in combination with MPA 
on working memory. Two previous studies have found that chronic MPA administered alone 
impairs working memory on the water radial arm maze (Braden et al., 2010; Braden et al., 2011).  
However, hormone treatment therapies contain MPA in combination with estrogen and the 
cognitive effects of these hormones may differ when administered alone. Although the present 
study found that E2 in combination with MPA improved performance on a working memory 
task, future studies should examine if this generalizes to other working memory tasks. 
Interestingly, long-term chronic oral E2 failed to alter performance on this task. Similar to our 
findings, chronic E2 administered both orally and via daily injections did not affect the number of 
working memory errors in the radial arm maze (Fernandez & Frick, 2004; Gresack & Frick, 
2006), and although chronic treatment with E2 minipellets decreased the number of reference 
memory errors in the radial arm maze there was no effect on working memory errors (Heikkinen 
et al., 2004). Studies using the operant versions of the delayed spatial alternation task 
consistently find that E2 administered chronically via silastic capsules during aging impairs 
performance (Neese et al., 2010; Wang, Neese, Korol, & Schantz, 2009) . Lesion studies indicate 
that the operant version of this task relies heavily on the mPFC (Sloan, Good, & Dunnett, 2006), 
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whereas performance on maze versions is altered by lesioning several different brain regions 
(Lalonde, 2002), indicating a fundamental difference between operant and maze versions. 
However, some studies have found improved performance after E2 treatment on working 
memory tasks. Long-term chronic E2 benefited acquisition of a delayed matching to position 
task, but similar to the present study, did not influence performance during delays (Gibbs, 2000). 
In addition, silastic capsules containing E2 improved performance on a spontaneous alternation 
task in aged mice (M. M. Miller et al., 1999). Importantly, the duration of hormone treatment in 
Miller et al. (1 month) differed greatly from the present study in which hormones were 
administered for approximately six months prior to behavioral testing which might explain the 
differences between these two studies.  
There is somewhat more agreement among studies evaluating the effects of estrogens on 
reference memory during aging. Several studies have found that  E2 or estradiol benzoate 
treatment in both middle aged and aged female rodents improves performance on the Morris 
water maze (Foster et al., 2003; Frick et al., 2002; Frye et al., 2005; Harburger et al., 2007; 
Lowry et al., 2010; Markham et al., 2002). It has become apparent that it is often not possible to 
generalize hormonal effects across different tasks and varying modes and lengths of 
administration (reviewed in Frick, 2009; J. M. Juraska & Rubinow, 2008). 
Most studies evaluating the neural effects of hormone treatments have administered hormones 
acutely. Acute E2 interacts with neurotransmitters systems, increases synaptophysin in the 
hippocampus, and increases neurotrophins in the entorhinal cortex (Bimonte-Nelson, Nelson, & 
Granholm, 2004; Frick et al., 2002; Gibbs, 1999). However, the few studies that have examined 
the neural outcomes of chronic long-term hormone treatment have found that changes observed 
with acute treatment return to baseline after chronic exposure. Chronic long-term treatment with 
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E2 down-regulates estrogen receptors (Brown, Scherz, Hochberg, & MacLusky, 1996), and 
levels of choline acetyltransferase increase after acute E2 treatment but return to normal after 
chronic treatment in the basal forebrain (Gibbs, 1997). Furthermore, acute treatment with 
estrogen and progesterone resulted in decreases in GABA receptor subunit expression 12 hours, 
but not 24 hours after treatment (Pazol et al., 2009). Therefore long-term chronic hormone 
treatment during aging might lead to a down regulation of estrogen receptors in cognitive brain 
regions and different behavioral outcomes than short term treatments.  
It has been suggested that hormone treatments that more closely mimic the natural cycle of 
hormones might be more beneficial for cognition (Frick, 2009). The present study found that E2 
administered cyclically resulted in a similar rate of acquisition to E2 administered chronically. 
Similar to the present study, continuous E2 treatment had no effect on spatial working or 
reference memory in the radial arm maze, while intermittent E2 treatment impaired spatial 
reference memory (Gresack & Frick, 2006). Cyclic administration of estradiol benzoate failed to 
improve performance on a 12-arm radial arm maze in middle aged female rats (Ziegler & 
Gallagher, 2005).  However, weekly injections of E2 plus progesterone enhanced performance of 
aged female rats on a delayed match-to-position T-maze task (Gibbs, 2000) and in aged rhesus 
monkeys, cyclic estradiol cypionate injections improved spatial working memory performance 
(P. R. Rapp et al., 2003). Continuous and intermittent E2 improved task acquisition in middle 
aged and aged animals (Bimonte-Nelson et al., 2006; Markowska & Savonenko, 2002). 
Although these studies found beneficial effects of cyclic treatment as compared to controls, none 
of the studies found that cyclic treatment was more beneficial for task performance than chronic 
treatment. However, most of these studies only simulated certain aspects of the cycle. For 
example, estrogen cyclicity was mimicked in the current study, but not the fluctuation in 
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progesterone levels. More closely simulating the natural cycle by including fluctuations in both 
estrogen and progesterone levels may be more beneficial than the chronic treatment of ovarian 
hormones. 
The route of administration used in a study can influence the outcome. Oral administration is the 
most common route of administration of hormone treatment in post menopausal women. Animal 
studies more commonly use injections or silastic capsules to deliver hormone treatments. These 
routes of administration have different pharmacokinetics than oral administration and do not 
allow for first pass metabolism of the hormone which may result in different outcomes of 
hormone treatment. Indeed, the only other study that has administered estradiol orally and 
examined effects on cognition in an animal model found improved performance on object 
recognition(Fernandez & Frick, 2004), while another study from the same lab found that daily 
injections of estradiol did not improve performance on the same task (Gresack & Frick, 2006). In 
the present study estradiol was administered orally both to model human treatment and to dose 
animals both cyclically and chronically. Although blood levels of estrogen are not available, 
group differences in body and uterine weights indicate that the treatment was physiologically 
effective, and preliminary results from a neuroanatomical study indicate treatment effects on 
brain structure (Packard, A.P., Lowry, N.C., Koss W.A., Juraska J.M., 2011).  
After the Women’s Health Initiative found that hormone treatment in postmenopausal women 
failed to enhance cognition and increased the number of subjects diagnosed with either probable 
dementia or mild cognitive impairment (Espeland et al., 2004; S. R. Rapp et al., 2003; Shumaker 
et al., 2003; Shumaker et al., 2004), researchers suggested that the presence of MPA in these 
hormone treatments might be responsible. However the current study found that E2 in 
combination with MPA is beneficial for certain tasks. Taken together with our previous studies, 
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these data emphasize the importance of avoiding generalizations between tasks, age, and length 
of replacement as well as time without estrogen. Elucidating the neural effects of long-term 
hormone treatments might help elucidate what determines the behavioral outcome.  
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Figures and Tables 
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Figure 5. Mean ± SEM number of sessions to criterion for no delay alternation trials.  Animals 
receiving E2 + MPA required fewer sessions to reach criterion than animals in three groups: no 
replacement (p < .04), chronic E2 (p < .02), and cyclic E2 (p < .02). There were non-significant 
trends for animals that received E2 + P to require fewer days to meet criterion than animals 
receiving chronic E2 (p < .09) and cyclic E2 (p < .08). * = p<.05 
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Figure 6. 
 
Figure 6. Mean number correct at each alternation delay. There was a significant effect of Delay 
(p <.01) such that increasing the intertrial delay significantly reduced performance in all 
treatment groups.  Hormone treatment was not significant.  
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Table 2. Body and Uterine Weight   
Hormone Group Mean Body Weight (g) Mean Uterine Weight 
No replacement 573.1 ± 24.4 .09 ±.01 
Chronic E2 469.8 ± 22.5* .15 ±.02* 
Chronic E2 & P 470.6 ± 19.93* .13 ± .01* 
Chronic E2 & MPA 466.8 ± 27.6* .16 ± .02* 
Cyclic E2 526.6 ± 23.4* .16 ± .01* 
(* = p< .05 compared to No replacement) 
Body and uterine weights were taken at sacrifice for all groups. No replacement animals weighed 
significantly more and had lower uterine weights that all hormone treated groups. * p <.01   
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CHAPTER 3 
EFFECTS OF LONG-TERM TREATMENT WITH ESTROGEN AND 
MEDROXYPROGESTERONE ACETATE ON SYNAPSE NUMBER IN THE MEDIAL 
PREFRONTAL CORTEX OF AGED FEMALE RATS.3 
 
  
                                                          
3 Previously published as: Chisholm NC & Juraska JM. Effects of long-term treatment with 
estrogen and medroxyprogesterone acetate on synapse number in the medial prefrontal cortex of 
aged female rats. Menopause. In press. 
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Abstract 
The present study investigated the effects of long-term hormone treatment, including the most 
commonly prescribed progestin, medroxyprogesterone acetate, during aging on synaptophysin 
labeled boutons, a marker of synapses, in the medial prefrontal cortex (mPFC) of rats. Female 
Long Evans hooded rats were ovariectomized at middle age (12-13 months) and were placed in 
one of 4 groups: no replacement (n=5), 17 β-estradiol alone (n=6), estradiol and progesterone 
(n=7) or estradiol and medroxyprogesterone acetate (n=4). Estradiol was administered in the 
drinking water and progestogens were administered via subcutaneous pellets that were replaced 
every 90 days. Following seven months of hormone replacement, animals were sacrificed and 
brains were stained for synaptophysin, a membrane component of synaptic vesicles. The density 
of synaptophysin labeled boutons was quantified in the mPFC using unbiased stereology and 
multiplied by the volume of the mPFC to obtain total number. Animals receiving estradiol and 
medroxyprogesterone acetate had significantly more synaptophysin labeled boutons in the 
medial prefrontal cortex than animals not receiving replacement (p<.03) and those receiving 
estradiol and progesterone (p<.02). In addition, there was a non significant trend for animals 
receiving estradiol alone to have more synapses than those receiving estradiol and progesterone. 
This study is the first to examine the effects of estradiol and medroxyprogesterone acetate during 
rat aging on cortical synaptic number. Estradiol with medroxyprogesterone acetate, but not 
progesterone, resulted in a greater number of synapses in the mPFC during aging than no 
replacement. 
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Introduction 
Menopause in humans is associated with a loss of ovarian hormones and this decline in estrogen 
and progesterone has been linked to several of the symptoms related to menopause.  Hormone 
therapies including Premarin (conjugated equine estrogens; CEE) and Prempro (CEE in 
combination with medroxyprogesterone acetate; MPA), have been approved to alleviate these 
symptoms. In women with a uterus, MPA, a synthetic analogue of progesterone, is administered 
in combination with estrogen therapy to prevent endometrial hyperplasia (Whitehead et al., 
1979). Along with alleviating some of the symptoms of menopause, hormone treatment has 
beneficial effects on cognition (Joffe et al., 2006; Krug et al., 2006; LeBlanc et al., 2001). 
However, results from the Women’s Health Initiative indicated that CEE alone or CEE 
administered with MPA results in an increased risk of stroke and dementia (Anderson et al., 
2004; Shumaker et al., 2003; Wassertheil-Smoller et al., 2003). There is evidence that the timing 
of hormone replacement onset is an important factor and may explain the negative findings of 
the Women’s Health Initiative studies (Daniel & Bohacek, 2010; Gibbs, 2000; Sherwin, 2009).  
Although data on the cognitive effects of hormone treatment in post-menopausal women seem 
inconsistent, several neurobiological studies have found that ovarian hormones increase synapses 
in the hippocampus of both young adult rats and non human primates. Ovariectomy decreased 
synapses in the CA1 region of the hippocampus (Gould, Woolley, Frankfurt, & McEwen, 1990) 
and estradiol administration increased the density of spines and synapses in the CA1 of young 
rats and non human primates (Adams et al., 2001; Choi et al., 2003; Leranth, Shanabrough, & 
Redmond, 2002; Woolley & McEwen, 1993). Chronic treatment with CEE increased synaptic 
density in the CA1 of young adult rats (Silva et al., 2000; Silva, Mello, Freymuller, Haidar, & 
Baracat, 2003). The synaptic response to estrogen is thought to involve estrogen receptor (ER)α 
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and ERβ, but the percentage of ERα labeled synapses (Adams et al., 2002) and the amount of 
ERβ (Yamaguchi-Shima & Yuri, 2007) decreases in the hippocampus during aging indicating 
that the aged brain might respond differently to estradiol. Indeed, estradiol increased 
synaptophysin, a membrane component of synaptic vesicles, in the CA1 of young animals but 
not in middle-aged rats (Williams et al., 2011).  Although estradiol increased NR1, a subunit of 
the NMDA receptor, in the hippocampus of aged animals, there was no increase in synapse 
number (Adams et al., 2001).  
Fewer studies have looked at the effects of hormone treatment on the prefrontal cortex (PFC), 
which exhibits greater neuroanatomical loss in both humans and other animals during aging than 
the hippocampus (J. M. Juraska & Lowry, 2011). Several studies have identified the human PFC 
as a region that has greater decline in gray matter volume during aging than other brain areas 
(Raz et al., 2005; Resnick et al., 2003). This change in volume is accompanied by age-related 
losses of dendrites and spines (de Brabander et al., 1998; Jacobs et al., 1997). There are also age-
related losses of dendrites and spines in the PFC of non-human primates (Cupp & Uemura, 1980; 
Duan et al., 2003) and rats (Grill & Riddle, 2002; Markham & Juraska, 2002; Wallace et al., 
2007). Similar to the hippocampus, estrogen can alter the structure of the PFC. Ovariectomy 
decreased spine density in the young adult rat PFC (Wallace et al., 2006) and estradiol benzoate 
increased spine synapse density in the PFC of young non-human primates (Leranth et al., 2008). 
Furthermore, long-term cyclic estradiol treatment increased dendritic spine density in the PFC of 
both young and aged rhesus monkeys (Hao et al., 2006; Tang et al., 2004), indicating that 
estradiol may affect the number of synapses in the aged PFC. In addition, intact females lose 
fewer spines during aging in the mPFC than males which may be due to the continued secretion 
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of estrogen and progesterone during estropause in rats (Markham & Juraska, 2002). To our 
knowledge, no study has examined the effects of progestogens on the PFC.  
Progestogens can alter the effects of estrogen on behavior in aging females (Lowry et al., 2010; 
Warren & Juraska, 2000) and may also change the effect of estrogen on synaptic numbers. The 
few studies that have investigated the effects of progestogens on synapse number have examined 
the hippocampus. Although progesterone administered alone increased the density of 
synaptophysin in young adult rhesus monkeys, progesterone administered with estrogen resulted 
in densities similar to ovariectomized controls (Choi et al., 2003). A more recent study found that 
estradiol in combination with progesterone increased synaptophysin in hippocampal CA1 of 
young rats but not middle-aged or aged animals (Williams et al., 2011). MPA is the progestin 
most commonly prescribed to women and very little is known about the neural effects of long-
term use. Both MPA and progesterone bind with high affinity to the progesterone receptor as 
well to the androgen and glucocorticoid receptors (Bamberger et al., 1999; Bardin et al., 1983; 
Sitruk-Ware, 2004). However, progesterone is readily metabolized to allopregnanolone 
(Majewska et al., 1986) whereas MPA inhibits the enzymes needed for this conversion (Jarrell, 
1984; Lee et al., 1999; Penning et al., 1985). Differences in mechanisms of action between these 
progestogens may result in divergent neural responses. Surprisingly only one study has evaluated 
the effects of MPA on synapse number. Chronic treatment with MPA alone or in combination 
with CEE resulted in an increase in the number of synapses in the hippocampus of young rats 
(Silva et al., 2000).  It is currently unknown if long-term treatment with MPA alters synapse 
number in the aged brain. 
The potential effects of estrogen and the addition of progestogens on the number of synapses in 
the PFC are especially pertinent, given the dramatic changes in the PFC during aging. Therefore, 
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the present study examined the effects of long-term chronic hormone treatment on the number of 
synaptophysin labeled boutons in the mPFC of aging females. 
Methods 
Subjects 
Subjects were 22 female Long Evans hooded rats purchased from Charles River Laboratories as 
retired breeders at the age of 11-12 months. Due to limited availability from the supplier, animals 
were run in two experimental cohorts. Animals from the same group were pair- or triple- housed, 
in clear Plexiglass cages in a temperature-controlled environment on a 12:12-hr light–dark cycle. 
Animals from these cohorts were used in two behavioral experiments prior to sacrifice 
(Chisholm & Juraska, 2012; Lowry et al., 2010). Standard rodent chow (Harlan 8604 Tekland) 
and water were available ad libitum to all animals, except during behavioral procedures during 
which the animals were maintained at 85-90% of their normal body weight.  All rats were 
handled, checked for health problems (tumors), and weighed weekly. At sacrifice, both body and 
uterine weight were measured. Animal care and experimental procedures were in accordance 
with National Institutes of Health guidelines and were approved by the Institutional Animal Care 
and Use Committee. 
Hormone Treatment 
All subjects were ovariectomized (OVX) at 12-13 months, because intact female rats continue to 
secrete low levels of ovarian hormones during aging (Markham & Juraska, 2002; Warren & 
Juraska, 2000; Wise & Ratner, 1980).  Subjects were anesthetized with 4% isoflurane and 
ovaries were removed via bilateral incisions. Animals were administered the analgesic, carprofen 
(0.05 mg/kg delivered intraperitoneally) prior to surgery and again 12 hours later, in accordance 
with animal care policy. Subjects were housed individually for five days following surgery to 
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allow for recovery and then returned to pair- or triple-housed conditions. Hormone 
administration was initiated the day of surgery and continued until sacrifice. Animals were 
randomly assigned into the following four groups: no replacement (n = 5), 17 β-estradiol (E2) (n 
= 6), E2 and MPA (E2 + MPA) (n = 4), E2 and progesterone (E2 + P) (n = 7). 
17 β-estradiol (E2) Administration. As in Lowry et al. (2010), all groups receiving estradiol 
were given E2 in their drinking water. A pilot study indicated that an E2 dose of 47ug/kg/day 
produced estrogen levels in the physiological range for this age group (25-30 pg/ml) (Markham 
& Juraska, 2002; Warren & Juraska, 2000). E2 was first dissolved in 95% ethanol (2mg/ml) and 
then dissolved in water as described in Gordon et al. (1986). Water consumption was measured 
weekly for each cage and remained between 60-80 ml/kg/day throughout the experiment for all 
groups. This range in water consumption resulted in E2 doses between 40-55 ug/kg/day The dose 
of E2 was calculated by taking the amount of water consumed by a cage and dividing by the sum 
of the weights in that cage. This value was then multiplied by the E2 concentration in the water. 
Water bottles were filled with new estrogen water every third day and stock estrogen water was 
stored in a dark refrigerator.  
Progestogen Treatment. On the day of OVX, one hormone pellet of either progesterone or MPA 
was inserted through a small incision in the nape of the neck in the appropriate groups. 
Progesterone pellets were made from silastic tubing (Dow Corning) packed with crystalline 
hormone. Studies have shown that 40 mm implants produce hormone levels between those found 
in aging female rats in persistent estrus and persistent diestrus (J. W. Liu et al., 1997).The MPA 
pellets (1.5mg) were purchased from Innovative Research of America. The 1.5mg 90-day release 
pellets result in a dose similar to that in women taking 2.5 mg per day when expected daily 
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release and average body weight are factored in. Progesterone and MPA pellets were replaced 
every 90 days. All other groups received sham surgeries at the time of pellet replacement. 
Histology 
At 19-20 months, after approximately 7 months of hormone treatment, rats were deeply 
anesthetized with sodium pentobarbital (2 mg/kg of a 50 mg/ml solution) and perfused 
intracardially with phosphate buffered saline followed with a solution of 4% paraformaldehyde, 
4% sucrose and 1.4% sodium cacodylate in dH2O. The brains were removed and stored in the 
same solution for 24 hours.  Brains were then transferred to a sodium cacodylate buffer solution 
and shipped at room temperature to Neuroscience Associates (Knoxville, TN) for sectioning. 
Briefly, brains were cryoprotected in a glycerol and DMSO-based formulation prior to 
sectioning. Fixed brains from each cohort were embedded together in a gelatin block that was 
frozen-sectioned at 30µm. Every tenth section was stained for synaptophysin, a membrane 
component of synaptic vesicles, and other sections were saved. Adjacent sections were stained 
with methylene blue/azure II, a cell body stain, in our laboratory for volume calculations. 
Volume estimation 
Using cytoarchitectonic criteria (Krettek & Price, 1977; Van Eden & Uylings, 1985) the ventral 
mPFC (prelimbic (PL) and infralimbic (IL)) regions were parcellated at 31.25× using a camera 
lucida on coded slides stained with methylene blue/azure II. The ventral mPFC was parcellated 
starting with the first section containing white matter continuing through the first section in 
which the genu of the corpus callosum appeared. This resulted in parcellation of both 
hemispheres in four to five sections per subject. Parcellation criteria used for the ventral mPFC 
have been described in Markham et al. (2007). For the present study, the PL and IL were not 
separated. The border between PL and dorsal anterior cingulate (Acd) is marked by a broadening 
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of layer V and an increase in the density of layer 3 cells in the Acd as compared to the PL 
(Figure 7). Layers 2/3 and 5/6 were measured separately (rat mPFC lacks layer 4). Camera lucida 
tracings were scanned into a computer and Image J (version 1.44, 2010) was used to measure the 
area of each parcellation. The volume was then calculated by multiplying this area by the 
mounted tissue thickness between sections. Mounted tissue thickness was measured by 
determining the difference between the focal depth of the top and bottom of the tissue using the 
StereoInvestigator software program (MicroBrightField). Ten measurements of thickness were 
taken per animal. An average section thickness was calculated per animal and used in the 
calculations for that animal. Mounted section thickness was equivalent among all groups. 
Randomly, animals were selected for re-parcellation and the area of the ventral mPFC was 
recalculated. This was done to insure consistency in parcellation criterion. Area measurements 
remained within 5% between parcellation drawings for a given animal.  
Synapse Number  
Synaptophysin boutons were quantified in the PL and IL of the mPFC using the 
StereoInvestigator software program (MicroBrightField). The optical disector was used to obtain 
stereologically unbiased counts of synaptophysin density in each layer of the mPFC (Figure 8).  
Using this program, contours were drawn of layers 2/3 and layers 5/6 in the ventral mPFC. Both 
hemispheres from two sections containing the mPFC were used for counts. At least 200 
synaptophysin boutons were counted within each layer (2/3, 5/6) for each subject. The area of 
the counting frame used was 4 µm × 4 µm with approximately 20 counting sites per section in 
both layers 2/3 and layers 5/6. Section thickness was used for dissector height excluding the 
.5 µm guard zones. Section thickness was measured at every fifth site on counted sections. 
Boutons fully inside the counting frame or those that contact the ‘inclusion’ line without 
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contacting the ‘exclusion’ line were included in counts (Figure 8). Average counts for each layer 
were divided by the volume of the counting frame to get the density of synaptophysin boutons. 
This density was then multiplied by the volume of the mPFC to obtain synapse number.  
Statistical Analysis 
Body weights, uterine weights, volume of the mPFC, and the total number of synaptic boutons, 
as well as those in layers 2/3 and in layers 5/6, were each analyzed using a one-way ANOVA 
with cohort as a covariate.  Fisher’s LSD tests were used for all post-hoc comparisons.  
Results 
Body and Uterine Weights 
The ANOVA revealed a significant effect of treatment on body weight (p < .01).  Post-hoc 
Fisher’s LSD revealed that the no replacement group weighed significantly more than all groups 
that received hormone treatment (E2: p < .01; E2 + P: p < .01; E2 + MPA: p < .01). No other 
comparisons reached significance (Table 3.) 
The ANOVA resulted in a significant effect of treatment on uterine weight (p < .02). Post-hoc 
Fisher’s LSD revealed that uterine weight in the no replacement group was significantly lower 
than all groups that received hormone treatment, indicating that hormone treatment was 
physiologically effective (E2: p < .01; E2 + P: p < .01; E2 + MPA: p < .01). 
Synapse Number 
Volume of the mPFC was not significantly different between any of the groups. There was an 
overall effect of hormone treatment on the total number of synaptophysin boutons in the mPFC 
(p < .05). Post-hoc tests revealed that animals receiving E2 + MPA had more synaptophysin 
boutons than those receiving no replacement (p <.03) and E2 + P (p <.02). There was a non 
significant trend for animals receiving estrogen alone to have more synaptophysin boutons than 
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those receiving E2 + P (p < .09) (Figure 9). For layers 2/3, hormone treatment did not alter 
synapse number (p = .17) (Figure 10A). Analysis of layers 5/6 found a significant effect of 
hormone treatment on the number of synaptophysin labeled boutons (p = .04). Post-hoc tests 
revealed that animals receiving E2 + MPA had more synaptophysin boutons that those receiving 
no replacement (p <.02) and E2 + P (p <.02) (Figure 10B). 
Discussion 
Long-term treatment with estradiol in combination with MPA to middle aged female rats 
resulted in greater numbers of synapses, as indicated by synaptophysin labeled boutons, in the 
mPFC as compared to ovariectomized controls. This is in agreement with the only other study to 
evaluate the effects of MPA on synapse number which found that MPA alone or administered 
with CEE increased synapses in the CA1 of young adult rats (Silva et al., 2000). Also, we have 
preliminary data showing that animals receiving estradiol in combination with MPA cyclically 
have greater numbers of synapses than ovariectomized controls (J. M. Juraska & Lowry, 2011). 
Importantly, synapse number decreases during aging (Gibson, 1983; Huttenlocher, 1979) and 
several measures related to synapse number are altered by aging in the PFC. There are age-
related losses of dendrites and spines in the PFC of humans (de Brabander et al., 1998; Jacobs et 
al., 1997), non human primates (Cupp & Uemura, 1980; Duan et al., 2003), and rats (Grill & 
Riddle, 2002; Markham & Juraska, 2002; Wallace et al., 2007). These changes have been linked 
to age related cognitive decline. For example, during aging, non human primates experience a 
decrease in the density of axospinal synapses in the PFC which correlates with acquisition of a 
delayed non-match to sample task (Dumitriu et al., 2010). Furthermore, age related deficits on an 
object recognition memory task are associated with decreases in dendritic spine density in the 
mPFC of rats (Wallace et al., 2007). Because aging has been associated with a loss of synapses 
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and this loss has been linked to cognitive deficits, the greater number of synapses in the aged 
PFC following long-term exposure to estradiol and MPA could result in beneficial effects on 
behavioral tasks mediated by the mPFC.  
However, few studies have evaluated the effects of estradiol in combination with MPA on 
cognition. MPA administered without estradiol impaired performance on the water radial arm 
maze and water maze (Braden et al., 2010; Braden et al., 2011). Although progesterone enhanced 
performance on the water maze and object recognition, MPA alone did not alter performance 
(Frye, Koonce, & Walf, 2010).  A subset of the animals in the present study was tested on the 
water maze, and estradiol plus MPA resulted in impaired performance as compared to other 
hormone treated groups (Lowry et al., 2010). In contrast, when many of the same subjects were 
tested on a delayed alternation t-maze task, treatment with estradiol in combination with MPA 
resulted in animals requiring fewer sessions to reach criterion (Chisholm & Juraska, 2012). The 
brain region mediating performance on a task may play an important role in determining the 
behavioral outcome of hormone treatment, and the studies that have found that MPA impairs 
cognition have used tasks that rely heavily on the hippocampus (Braden et al., 2010; Braden et 
al., 2011; Lowry et al., 2010). The present study found that estradiol plus MPA results in more 
synaptophysin labeled boutons as compared with ovariectomized controls in the mPFC, 
suggesting that this combination of hormone treatment may be beneficial on tasks that rely more 
heavily on the mPFC. 
Unlike estradiol and MPA, estradiol plus progesterone did not affect the number of 
synaptophysin labeled boutons. Although MPA is a synthetic analogue of progesterone, studies 
have found that these two progestogens do not share identical biological properties. MPA has a 
higher affinity for androgen and glucocorticoid receptors than progesterone (Bamberger & 
65 
 
Schulte, 2000) and progesterone is readily metabolized to allopregnanolone (Majewska et al., 
1986) while MPA inhibits the enzymes needed for this conversion (Jarrell, 1984; Lee et al., 
1999; Penning et al., 1985). Several studies have found that these two progestogens result in 
differential neural outcomes. For example, MPA, but not progesterone, suppresses cytokine 
production after an inflammatory stimulus in vitro (Bamberger et al., 1999). In addition, in vitro 
studies have found that progesterone protected against kainic acid-induced neuronal loss while 
MPA did not (Ciriza et al., 2006). Progesterone alone and in combination with estrogen 
protected against glutamate toxicity while MPA was not protective and prevented estradiol’s 
influence on neuroprotection (Nilsen & Brinton, 2002a; Nilsen & Brinton, 2003).  Also, 
treatment with estradiol and progesterone but not MPA, increased proliferation of 
neuroprogenitor cells in culture (L. Liu et al., 2010). Furthermore, progesterone increased levels 
of brain-derived neurotrophic factor while MPA decreased this measure (Jodhka, Kaur, 
Underwood, Lydon, & Singh, 2009). Although MPA and progesterone treatments without 
estrogen decreased levels of glutamic acid decarboxylase in the hippocampus, this decrease was 
only significant in those receiving MPA (Braden et al., 2010). Interestingly, most of these studies 
indicate a beneficial effect of progesterone on the measures evaluated, which was not found in 
the present study; however none of these studies examined synapse number or the importance of 
neuroprotection during normal aging. The current study administered hormones for 
approximately seven months in order to evaluate the long-term effects of hormone treatment and 
many of the previous studies have used acute treatments. Studies have found that chronic 
treatment of ovarian hormones results in different outcomes than more acute treatments (Gibbs, 
1997; Morissette & Di Paolo, 1993; Pazol et al., 2009). It is possible that long-term hormone 
treatment results in receptors that are less sensitive and thus after several months of treatment 
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outcomes observed after acute treatment may return to baseline levels. It is unknown if long-term 
treatment with these two progestogens would affect receptors in a similar manner. Furthermore, 
previous studies comparing these progestogens have examined the effects on the hippocampus, 
and it is known that the anatomical structure of the PFC is particularly vulnerable to aging, while 
the hippocampus is not (reviewed in J. M. Juraska & Lowry, 2011). It is possible that because 
the hippocampus and mPFC respond differently to aging they are differentially affected by 
progestogens administered during this time. 
Estrogen is known to alter several aspects of synaptic communication in young rats. For 
example, estrogen administered to ovariectomized animals, returns synaptophysin levels and 
spine densities in the CA1 to levels observed in intact controls (Gould et al., 1990; Williams et 
al., 2011; Woolley & McEwen, 1992). Also, ovariectomy decreases synaptophysin levels in the 
inner layer of the dentate gyrus and estrogen restores this (Stone, Rozovsky, Morgan, Anderson, 
& Finch, 1998). However, the aged hippocampus appears to be less responsive to the effects of 
estrogen. Estrogen treatment did not increase synapse density in the CA1 of aged animals 
(Adams et al., 2001) and there are decreased amounts of synaptic ERα immunoreactivity in this 
brain region (Adams et al., 2002). In addition, estradiol increased the amount of synaptophysin 
and opioid peptides in the CA1 and dentate gyrus of young animals, but did not alter the amount 
in aged animals (Williams et al., 2011). The present study found that long-term estrogen 
marginally increased synapses in the aged mPFC suggesting that in contrast to the hippocampus, 
the mPFC may remain responsive to estrogens during aging. This is in agreement with previous 
studies in non human primates. Long-term cyclic treatment with estradiol increased apical and 
basal dendritic spine density in the PFC of aged female rhesus monkeys and reversed age-related 
impairments on a delayed response task mediated by the PFC (Hao et al., 2006; P. R. Rapp et al., 
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2003). It is important to note that the means in the present study were in the direction of estrogen 
treated animals having more synapses although it did not reach significance. Studies have found 
that rodent diets high in phytoestrogens result in a greater density of spines in both the 
hippocampus and PFC (V. Luine, Attalla, Mohan, Costa, & Frankfurt, 2006). As in most of the 
literature, animals in the present study were maintained on a standard rodent diet and it is 
possible that the low levels of soy in the diet increased the number of synaptophysin boutons in 
our no replacement animals minimizing differences between groups (Leranth et al., 2008). The 
differences that were found are especially notable in light of this possibility. 
The effects of estrogen on synapse number have been shown to be mediated through estrogen 
receptors (F. Liu et al., 2008; Srivastava, Woolfrey, Liu, Brandon, & Penzes, 2010). However, 
because the effects of estrogen alone were subtle in the current study and the addition of MPA 
led to significantly more synapses as compared to no replacement, it seems likely that this effect 
was mediated by a different mechanism. Research suggests that synapse number is also regulated 
by IGF-1. IGF-1 null animals have decreased dendritic length and spines in the frontoparietal 
cortex (Cheng et al., 2003) and over expression of IGF-1increases the number of synapses in the 
dentate gyrus (O'Kusky, Ye, & D'Ercole, 2000). Importantly, IGF-1 protein levels are decreased 
during aging (Sonntag et al., 1999) and modulated by steroid hormones (Selvamani & Sohrabji, 
2010a). Estrogen alone has been found to decrease IGF-1levels; however, estrogen administered 
with MPA resulted in an increase in IGF-1 in post-menopausal women (Malarkey et al., 1997) 
while estradiol administered with natural progesterone does not (Mozzanega et al., 2007). 
Therefore, the effects of estrogen in combination with MPA on synapse number seen in the 
current study may be mediated in part by increasing IGF-1 levels.   
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Given the vulnerability of the PFC to the effects of aging, the alteration of the mPFC by hormone 
treatment during aging may have implications for age-related cognitive deficits. Results from the 
current study indicate that the aged PFC remains responsive to certain hormone treatments and 
thus these treatments may protect against age-related cognitive deficits. Indeed, treatment with 
acute estrogen alone given to postmenopausal women benefited tasks relying on the PFC to a 
greater extent than those relying on the hippocampus (Krug et al., 2006). In addition, women not 
receiving estrogen replacement performed worse on several PFC dependant tasks than those 
receiving hormone treatment (Keenan et al., 2001).  Future studies in humans should evaluate the 
effects of long-term hormone treatment, including the addition of a progestogen on PFC 
dependant tasks. 
Conclusions 
This study identifies the prefrontal cortex as a brain region that is altered by long-term chronic 
hormone treatment during aging in the rat. Specifically, treatment with estradiol and MPA 
resulted in more synaptophysin labeled boutons in the mPFC relative to females with no 
replacement or replacement with estradiol and progesterone.  These findings provide insight into 
the neural effects of long-term hormone treatment. 
  
69 
 
Figures and Tables 
 
 
 
Figure 7.     Figure  8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Coronal section through the medial prefrontal cortex with cell bodies stained using 
Methylene blue/Azure II. Borders of the prelimbic and infralimbic regions are shown based on 
the cytoarchitectonic characteristics revealed by this stain (Krettek & Price, 1977; Van Eden & 
Uylings, 1985).  Reprinted from Markham et al. (Markham et al., 2007). 
 
Figure 8. High magnification image of the mPFC stained for synaptophysin, a membrane 
component of synaptic vesicles. The counting frame used to stereologically quantify the number 
of boutons was 4 µm by 4 µm. 
70 
 
Figure 9. 
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Figure 9. Total number (mean + SEM) of synaptophysin labeled synaptic boutons in the mPFC. 
Animals receiving E2 + MPA had more synaptophysin boutons than those receiving no 
replacement and E2 + P. There was a non significant trend for animals receiving estrogen alone 
to have more synaptophysin boutons than those receiving E2 + P (*p <.03, #p < .09). 
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Figure 10.  
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Figure 10. Total number (mean + SEM) of synaptophysin labeled synaptic boutons in Layers 2/3 
of the mPFC. Hormone treatment did not significantly alter the number of synapses. B. Total 
number (mean + SEM) of synaptophysin labeled boutons in Layers 5/6 of the mPFC. Animals 
receiving E2 + MPA had more synaptophysin labeled boutons that those receiving no 
replacement and E2 + P (*p <.02). 
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Table 3. Body and Uterine Weight 
Hormone Group Mean Body Weight (g) Mean Uterine Weight (g) 
No replacement 619.6 ± 37.7 .05 ±.01 
Estrogen 501.8 ± 35.0* .12 ±.02* 
Estrogen & P 472.7 ± 28.1* .11 ± .01* 
Estrogen & MPA 451.3 ± 66.2* .12 ± .02* 
 
Body and uterine weights were taken at sacrifice for all groups. No replacement animals weighed 
significantly more and had lower uterine weights that all hormone treated groups. * p <.01   
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CHAPTER 4 
THE EFFECTS OF LONG-TERM TREATMENT WITH ESTRADIOL AND 
MEDROXYPROGESTERONE ACETATE ON TYROSINE HYDROXYLASE FIBERS AND 
NEURON NUMBER IN THE MEDIAL PREFRONTAL CORTEX OF AGED FEMALE 
RATS.4 
 
                                                          
4 Submitted for publication as: Chisholm NC, Packard AR, Koss WA, Juraska JM. The effects of 
long-term treatment with estradiol and medroxyprogesterone acetate on tyrosine hydroxylase 
fibers and neuron number in the medial prefrontal cortex of aged female rats. Endocrinology 
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Abstract 
Menopause in humans is associated with undesirable side effects and many women initiate 
hormone treatment therapies to alleviate these symptoms. Research suggests that these 
treatments may also affect cognition, and studies in young animals indicate that hormone 
treatment can alter several neuroanatomical measures. However, very little is known about the 
effects of long-term hormone treatment on the aging female brain. This study investigated the 
effects of hormone treatment on neuron number and tyrosine hydroxylase fibers in the rat medial 
prefrontal cortex (mPFC). Female Long Evans rats were ovariectomized at middle age (12-13 
months) and placed in one of 4 groups: no replacement, estradiol (E2), E2 and progesterone, or E2 
and medroxyprogesterone acetate (MPA). At 20 months of age, animals were sacrificed and the 
brains were Nissl stained and immuno-stained for tyrosine hydroxylase.  Neuron number and 
tyrosine hydroxylase fiber density were quantified in the mPFC. Hormone treatment did not alter 
neuron number. Treatment with E2 and MPA resulted in greater tyrosine hydroxylase densities 
than no replacement animals in layer 1 and layers 2/3 (p< .05).  In layers 2/3, animals receiving 
E2 also had greater tyrosine hydroxylase densities than no replacement animals (p< .01). These 
results indicate that long-term hormone treatments alter dopaminergic fibers and potentially the 
functioning of the aging mPFC. 
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Introduction 
 Gonadal hormone levels decrease in both men and women during aging (reviewed in 
(Lamberts, van den Beld, & van der Lely, 1997); however aging females experience a dramatic 
decrease in ovarian hormones at the onset of menopause. Many women initiate hormone 
treatment therapies, including Premarin (conjugated equine estrogens; CEE) and Prempro (CEE 
in combination with medroxyprogesterone acetate; MPA), to alleviate the symptoms of 
menopause, and the presence of these hormones may alter the course of aging in females. Indeed, 
women using estrogen therapy during menopause have a greater gray matter density in superior 
frontal gyrus than non users (Lord, Engert, Lupien, & Pruessner, 2010) and non-users have lower 
gray matter concentration in orbitofrontal cortices than both estrogen users and young women 
(Robertson et al., 2009). However, the Women’s Health Initiative found that CEE alone or CEE 
administered with MPA results in an increased risk of stroke and dementia (Anderson et al., 
2004; Shumaker et al., 2003; Wassertheil-Smoller et al., 2003). More recent studies suggest that 
the timing of hormone replacement initiation may explain the negative findings of the Women’s 
Health Initiative studies (Daniel & Bohacek, 2010; Gibbs, 2000; Sherwin, 2009).   
 The effects of hormone treatment on the prefrontal cortex are especially important given 
the changes that are occurring in this brain region during human aging. The prefrontal cortex has 
been identified as a region that has greater decline in gray matter volume during aging than other 
brain areas (Raz et al., 2005; Resnick, Pham, Kraut, Zonderman, & Davatzikos, 2003). 
Decreases in synaptic density, spine density, and dendritic arborization have also been found in 
the aged human frontal cortex (de Brabander, Kramers, & Uylings, 1998; Huttenlocher, 1979; 
Jacobs, Driscoll, & Schall, 1997; Masliah, Mallory, Hansen, DeTeresa, & Terry, 1993). In the 
mPFC of aged rats, reductions have been found in both spine density and arborization of 
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dendrites (Grill & Riddle, 2002; Markham & Juraska, 2002; Wallace, Frankfurt, Arellanos, 
Inagaki, & Luine, 2007). In addition, a loss of neurons has been observed in the aging human 
cortex overall (Pakkenberg & Gundersen, 1997) and in the PFC during aging in non-human 
primates and rodents (Smith, Rapp, McKay, Roberts, & Tuszynski, 2004; Yates, Markham, 
Anderson, Morris, & Juraska, 2008). However, there is evidence from our lab that this loss is 
sexually dimorphic with males, but not females, losing neurons during aging in the mPFC (Yates 
et al., 2008). The presence of low levels of ovarian hormones in rats after the cessation of the 
cycle (Dudley, 1982) may protect females from this age-related neuron loss, thus providing a 
possible mechanism by which hormone treatment decreases shrinkage associated with aging. 
There is extensive research demonstrating the neuroprotective properties of estradiol in culture or 
young animals (Garcia-Segura, Azcoitia, & DonCarlos, 2001); however, more recent work finds 
that estradiol is not neuroprotective in a middle-aged stroke model (Selvamani & Sohrabji, 
2010a). In addition, estrogen and progesterone have been shown to have neuroprotective 
properties in vitro; whereas MPA counteracts the neuroprotective effects of estrogen (Nilsen & 
Brinton, 2002b). It is unknown how neuroprotection relates to normal aging and to date there 
have been no studies examining the effects of hormone treatment during aging on neuron number 
in the mPFC. 
Ovarian hormones are known to alter several neuroanatomical measures including 
synapse number and spine density in the prefrontal cortex of young (Leranth, Hajszan, Szigeti-
Buck, Bober, & MacLusky, 2008; Tang et al., 2004) and aged rhesus monkeys (Hao et al., 2006). 
In addition, a recent study from our lab found that long-term treatment with estradiol in 
combination with MPA during aging resulted in a greater number of synapses than no 
replacement animals (Chisholm & Juraska, in press). This alteration in synapse number could 
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result from several different cellular changes including preservation of neurotransmitter 
functioning. Dopamine is of particular interest because of the changes that are known to occur in 
this system during aging in the PFC. For example, dopamine receptors decrease during aging in 
humans, nonhuman primates and rodents (de Keyser, De Backer, Vauquelin, & Ebinger, 1990; 
Gozlan et al., 1990; Lai, Bowden, & Horita, 1987; Seeman et al., 1987), with the fastest rate of 
decline commonly found in the frontal cortex (Inoue et al., 2001; Kaasinen et al., 2000; Kaasinen 
et al., 2002). Dopaminergic functioning in the PFC is also altered by ovarian hormones. Levels 
of dopamine fluctuate in the prefrontal cortex across the estrous cycle in intact animals (Dazzi et 
al., 2007). Furthermore, acute estradiol and an ER β agonist, increased dopamine metabolites in 
the PFC of young adult rats (Inagaki, Gautreaux, & Luine, 2010; Jacome et al., 2010), and 
tyrosine hydroxylase (TH) immunoreactivity in the PFC of adult female monkeys is decreased 
after ovariectomy and restored with estradiol administered with progesterone (Kritzer & 
Kohama, 1998; Kritzer & Kohama, 1999). However the effects of ovarian hormones during 
aging on this neurotransmitter system have not been thoroughly investigated and it is possible 
that effects of hormone treatment may be different in young and aged animals. 
The present study administered different combinations of long-term hormone treatments 
to aging female rats to determine the effects on both neuron number and dopaminergic fibers.  
Middle aged female rats were ovariectomized, and placed in one of four groups: no replacement, 
estrogen only, estrogen and progesterone, estrogen and MPA.  Differences between groups of 
animals may suggest distinct roles for estrogen and progestagens during aging and provide 
insight into how hormone treatments may alter the course of normal aging.   
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Methods 
Subjects 
Subjects were female Long Evans hooded rats purchased from Charles River Laboratories as 
retired breeders at the age of 11-12 months. Due to limited availability from the supplier, animals 
were run in three experimental cohorts. Animals from all cohorts were included in the analysis of 
neuron number (n=41) and animals from cohorts 1 and 2 were included in the analysis of 
tyrosine hydroxylase density (n=21). Animals from the same group were pair- or triple- housed, 
in clear cages on a 12:12-hr light–dark cycle. Standard rodent chow (Harlan 8604 Tekland) and 
water were available ad libitum to all animals, except during behavioral procedures (Chisholm & 
Juraska, 2012) during which the animals were maintained at 85-90% of their normal body 
weight.  All rats were handled, checked for health problems (tumors), and weighed weekly. Both 
body and uterine weight were measured at sacrifice. Animal care and experimental procedures 
were in accordance with National Institutes of Health guidelines and were approved by the 
Institutional Animal Care and Use Committee.  
Hormone Treatment 
Subjects were ovariectomized (OVX) at 12-13 months under isoflurane anesthesia. Hormone 
administration was initiated the day of surgery and continued until sacrifice. Animals were 
randomly placed in one of the following four groups: no replacement (NR) (n = 12), 17 β-
estradiol (E2) (n = 12), E2 and progesterone (E2 + P) (n = 7) or E2 and MPA (E2 + MPA) (n = 10). 
17 β-estradiol (E2) Administration. As in Chisholm & Juraska (2011) all groups receiving 
estradiol were given E2 in their drinking water. E2 was first dissolved in 95% ethanol (2mg/ml) 
and then dissolved in water as described in Gordon et al.(1986). A pilot study found that an E2 
dose of 47µg/kg/day resulted in estrogen levels in the physiological range for this age group (25-
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30 pg/ml) (Markham & Juraska, 2002; Warren & Juraska, 2000). Water consumption was 
measured weekly for each cage and remained between 60-80 ml/kg/day throughout the 
experiment for all groups. This resulted in E2 doses between 40-55 µg/kg/day. The dose of E2 
was calculated by taking the amount of water consumed by a cage and dividing by the sum of the 
weights in that cage. This value was then multiplied by the E2 concentration in the water.  
Progestogen Treatment. At the time of OVX, one hormone pellet of either progesterone or MPA 
was inserted in the nape of the neck in the appropriate groups. Progesterone pellets were 40 mm 
in length and made from silastic tubing (Dow Corning) packed with crystalline hormone. Studies 
have shown that 40 mm implants produce hormone levels between those found in aging female 
rats in persistent estrus and persistent diestrus (J. W. Liu, Dawson, Peters, Baker, & Walker, 
1997). MPA pellets (1.5mg) were purchased from Innovative Research of America. The 1.5mg 
90-day release pellets result in a dose similar to that in women taking 2.5 mg per day when 
expected daily release and average body weight are factored in. Progesterone and MPA pellets 
were replaced every 90 days and all other groups received sham surgeries at the time of pellet 
replacement. 
Histology 
At approximately 20 months, after 8 months of hormone treatment, rats in cohorts 1 and 
2 (n=21) were deeply anesthetized with sodium pentobarbital (2 mg/kg of a 50 mg/ml solution) 
and perfused intracardially with phosphate buffered saline followed with a solution of 4% 
paraformaldehyde, 4% sucrose and 1.4% sodium cacodylate in dH2O. The brains were removed 
and stored in the same solution for 24 hours.  Brains were then transferred to a sodium 
cacodylate buffer solution and shipped at room temperature to Neuroscience Associates 
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(Knoxville, TN) for sectioning. Unstained 30 µm sections were returned to our lab where they 
were stained with methylene blue/azure II, a cell body stain, and for tyrosine hydroxylase.  
The third cohort of animals (n=20) were only used for neuron counts and were processed 
according to the following methods. All rats were deeply anesthetized with sodium pentobarbital 
(2 mg/kg of a 50 mg/ml solution), and intracardially perfused with Ringer’s wash (2 minutes) 
followed by a solution of 4% paraformaldehyde in 0.1 M phosphate buffer. Brains were removed 
and stored in a solution of 4% paraformaldehyde in 0.1 M phosphate buffer for 21 days, followed 
by cryoprotection in 30% sucrose for three days. Brains were coronally sectioned and 60 µm 
thick sections were mounted then stained with methylene blue/azure II.  
Immunohistochemistry 
 Sections from cohorts 1 and 2 (NR (n = 5); E2 (n = 6); E2 + MPA (n = 4); E2 + P (n = 6)) 
were immunoreacted according to procedures found in Adler et al. (1999) with a few 
modifications. Sections were rinsed in 0.1 M PBS, pH 7.4 (3 X 15 minutes), incubated in 1% 
H2O2 in PBS for 30 min. Sections were then rinsed in Tris-buffered saline (TBS 3 X 15 minutes), 
pH 7.4, placed in blocking solution (TBS containing 10% normal swine serum; NSS) for 2 hours, 
and incubated in primary antiserum (diluted in TBS containing 1% NSS, two days, 4°C). Anti-
TH antibodies (Chemicon International, Temecula, CA) were used at a working dilution of 
1:1000. Following incubation in primary antibody, sections were rinsed in TBS, placed in 
biotinylated secondary antibodies (Vector, Burlingame, CA; 2 h room temperature; 1:100), 
rinsed in TBS, and then incubated in avidin–biotin-complexed horseradish peroxidase for two 
hours at room temperature (ABC; Vector, Burlingame, CA). Sections were then rinsed in TBS, 
pH 7.4 and reacted by using Sigma Fast Tabs (Sigma, Saint Louis, MO). Sections were 
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immediately mounted and allowed to dry overnight. The following day, slides were dehydrated 
and coverslipped. 
Volume estimation 
Using cytoarchitectonic criteria (Krettek & Price, 1977; Van Eden & Uylings, 1985) the 
ventral mPFC (prelimbic (PL) and infralimbic (IL)) regions were parcellated at 31.25× using a 
camera lucida on coded slides stained with methylene blue/azure II. The ventral mPFC was 
parcellated starting with the first section containing white matter continuing through the first 
section in which the genu of the corpus callosum appeared. This resulted in parcellation of both 
hemispheres in four to five sections per subject. Parcellation criteria used for the ventral mPFC 
have been described in Markham et al.(2007).  Layers 2/3 and 5/6 were measured separately (rat 
mPFC lacks layer 4). Camera lucida tracings were scanned into a computer, and Image J (version 
1.44, 2010) was used to measure the area of each parcellation. The volume was then calculated 
by multiplying this area by the mounted tissue thickness between sections. Mounted tissue 
thickness was measured by determining the difference between the focal depth of the top and 
bottom of the tissue using the StereoInvestigator software program (MicroBrightField, Chicago, 
IL). An average section thickness was calculated per animal and used in the calculations for that 
animal.  
Neuron number estimation 
Neurons were quantified in the PL and IL of the mPFC using the StereoInvestigator 
software program (MicroBrightField). The optical disector was used to obtain stereologically 
unbiased counts of cell density in each layer of the mPFC. Using this program, contours were 
drawn of layers 2/3 and layers 5/6 in the ventral mPFC and at least 200 neurons were counted 
within each layer (2/3, 5/6) for each subject. Section thickness was measured at every fourth site 
82 
 
on counted sections. Only neurons fully inside the counting frame or those that contact the 
‘inclusion’ line without contacting the ‘exclusion’ line were included in counts. Average counts 
for each layer were divided by the volume of the counting frame to calculate the cell density. 
This number was then multiplied by the volume to obtain cell number. 
Fiber Density 
 
Examination of tyrosine hydroxylase immunoreactive fibers was carried out in two PFC-
containing sections (300µm apart) of each brain. Z-stacked images were acquired using a Zeiss 
Axiovert 200M fluorescence microscope (Carl Zeiss, Thornwood, NY) and compressed using 
Axiovision software (Figure 11A). Within each layer of the PFC (1, 2/3, and 5/6), three pictures 
were taken (two in the PL one in the IL). A total of 18 pictures were taken per animal (9 per 
section). 
Image J was used to measure image pixel density (the percent of the image in black) in 
two ways: first as a binary image, taking thickness into account (Figure 11B), and then as a 
skeletonized image, reducing the thickness to 1 pixel wide (Figure 11C). Skletonized images 
were analyzed because previous studies that have quantified tyrosine hydroxylase fibers used this 
type of image (Kritzer & Kohama, 1999); binary images were quantified to determine if fiber 
thickness might be altered. In addition, the binary images were mulitplied by the volume of the 
mPFC for each animal to test whether the total volume of TH fibers differed between groups. 
Statistical analysis 
Body and uterine weights were analyzed using a one-way ANOVA with cohort as a 
covariate. Neuron number was analyzed using a one-way ANOVA with cohort as a covariate for 
each layer separately and then with all layers combined for total neuron number in the mPFC. 
The total pixel density percentage and the total volume of TH immunoreactive fibers in both 
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binary and skeletonized images were analyzed using a one-way ANOVA for layer 1 and layers 
2/3 separately. TH fibers were not analyzed in layers 5/6 due to the dark background in the 
images acquired. Fisher’s LSD tests were used for all post hoc comparisons.  
Results 
Body and Uterine Weights 
 Hormone treatment significantly affected body weight in animals used for neuron number 
analysis (F (3, 36) = 9.897, p < 0.01).  Post-hoc Fisher’s LSD revealed that the no replacement 
group weighed significantly more than all groups that received hormone treatment (E2: p < .01; 
E2 + P: p < .01; E2 + MPA: p < .01). No other comparisons reached significance (Table 4). 
Analysis of animals that were used only for tyrosine hydroxylase analysis also resulted in a 
significant effect of treatment on body weight. 
 Uterine weight was significantly altered by hormone treatment in animals used for neuron 
number analysis (F (3, 36) = 11.197, p < 0.01).  Post-hoc Fisher’s LSD revealed that uterine 
weight in the no replacement group was significantly lower than all groups that received 
hormone treatment, indicating that hormone treatment was physiologically effective (E2: p < .01; 
E2 + P: p < .01; E2 + MPA: p < .01) (Table 4). There was also a significant effect of treatment on 
uterine weight in animals that were used only for tyrosine hydroxylase. 
Neuron Number and Volume 
Hormone treatment did not significantly alter volume or neuron number in any layer or in all 
layers combined of the mPFC (Figure 12). 
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 Tyrosine Hydroxylase 
Layer 1 
Analysis of binary images in layer 1 found that hormone treatment significantly altered 
the total number of TH immunoreactive fibers (F (3, 17) = 3.903, p < 0.03) (Figure 13A). Post-
hoc tests showed that animals receiving E2+MPA had a higher density of TH immunoreactive 
fibers than those receiving no replacement (p < 0.01) and than those receiving E2+P (p < 0.02). 
There was a trend for animals who received E2 to have a higher TH fiber pixel density than 
animals who received no hormone replacement (p = 0.06). Analysis of the skeletonized images 
revealed a similar pattern within layer 1 (F (3, 17) = 2.648, p < 0.09) (Figure 13B). Post-hoc tests 
demonstrated that animals receiving E2 +MPA had a significantly higher density of TH fibers 
than those receiving no replacement (p < 0.03) and a weak trend (p < 0.08) toward E2 +MPA 
having higher pixel densities than E2 +P (Figure 3B). There was a trend (p = 0.06) for E2 animals 
to have a higher pixel density percentage than NR animals. There was an effect of hormone 
treatment on the volume of tyrosine hydroxylase fibers (F (3, 16) = 4.286, p < 0.03) and post-hoc 
tests found the same group differences as the analysis of fiber density (Figure 14A). 
Layers 2/3 
 Analysis of the binary images found that hormone treatment significantly altered the TH 
immunoreactive fiber density within layers 2/3 (F (3,15) = 3.387, p < 0.05)(Figure 15A).  Post-
hoc tests demonstrated that animals receiving E2 and E2 +MPA had significantly higher TH fiber 
densities than no replacement animals (p < 0.05) (Figure 15A). There was a trend for animals 
receiving E2 +P to have more TH fibers than no replacement (p < .06). Analysis of skeletonized 
images revealed a significant effect of hormone treatment on pixel density percentage of TH 
immunoreactive fibers in layers 2/3 F (3, 15) = 6.496, p < 0.01) (Figure 15B).  Post-hoc analysis 
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found that all hormone treated groups had greater TH fiber density than no replacement animals 
(E2 +MPA: p = 0.02; E2 +P: p < 0.05; and E2: p = 0.001).  In addition, the E2 only group had a 
significantly higher pixel density than the E2 +P group (p < 0.03). There was also a main effect of 
hormone treatment on the volume of tyrosine hydroxylase fibers (F (3, 14) = 3.721, p < 0.04). 
Post-hoc tests found that animals receiving E2+MPA and E2 alone had significantly higher 
volumes of TH than no replacement animals (p < .02). There was a trend for animals receiving 
E2 +P animals to have a greater volume of TH than no replacement animals (p < 0.07) (Figure 
14B).  
The volume of TH fibers and the number of synaptophysin labeled boutons in the mPFC 
found in our previous study (Chisholm & Juraska, in press) were examined using Pearson 
correlation analysis. In layers 2/3 the volume of TH fibers showed a positive correlation with the 
number of synaptophysin labeled boutons (r = .44, p < .05) (Figure 16). 
Discussion 
 Long-term treatment of middle aged female rats with estradiol alone and in combination 
with MPA resulted in a greater density of tyrosine hydroxylase fibers in the mPFC as compared 
to ovariectomized controls. This is the first study to evaluate the effects of long-term estrogen 
treatment with or without MPA, on the prefrontal dopaminergic system during aging in females. 
However, these results are congruent with several studies in young animals that find that the 
prefrontal dopaminergic system is influenced by ovarian hormones. (Dazzi et al., 2007; Inagaki 
et al., 2010; Kritzer & Kohama, 1998; Kritzer & Kohama, 1999). Although no studies have 
looked at the prefrontal cortex during aging, the effects of acute estrogen treatment on the aged 
striatum have been examined. Acute estradiol benzoate increased basal dopamine levels in the 
striatum of both young and aged rats, while a similar treatment increased dopamine receptors in 
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the striatum of young females, but not middle aged females (McDermott, 1993; Roy, Sheinkop, 
& Wilson, 1982). The changes in the dopaminergic system found after long-term treatment with 
estradiol and MPA in the current study are also consistent with the greater number of synapses 
found in a previous study from our lab after the same treatment (Chisholm & Juraska, in press). 
Because dopamine fibers are known to decrease with normal aging in the prefrontal cortex 
(Mizoguchi, Shoji, Tanaka, Maruyama, & Tabira, 2009), it is most likely that this hormone 
treatment is preventing the normal loss associated with aging, rather than by causing new fibers 
to innervate the prefrontal cortex. 
 Interestingly, estradiol in combination with progesterone did not consistently result in a 
greater density of tyrosine hydroxylase fibers. In fact, in layer 1 of the mPFC, not only did 
estrogen with progesterone not alter tyrosine hydroxylase fibers compared to controls, it resulted 
in fewer fibers than estradiol in combination with MPA. This finding is in agreement with our 
previous study which found that long-term estradiol in combination with MPA resulted in a 
greater number of synapses, while estradiol with progesterone failed to alter synapse number 
(Chisholm & Juraska, in press). MPA is a synthetic analogue of progesterone; however these two 
progestogens do not share identical biological properties. For example, progesterone is 
metabolized to allopregnanolone (Majewska, Harrison, Schwartz, Barker, & Paul, 1986) while 
MPA inhibits the enzymes required for this conversion (Jarrell, 1984; Lee, Miller, & Auchus, 
1999; Penning, Sharp, & Krieger, 1985) and MPA has a higher affinity for androgen and 
glucocorticoid receptors than progesterone (Bamberger & Schulte, 2000). These two 
progestogens often result in differential neural outcomes although most of these studies indicate 
a beneficial effect of progesterone on the measures evaluated. For example, progesterone alone 
and in combination with estrogen protected against glutamate toxicity while MPA was not 
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protective and prevented estradiol’s influence on neuroprotection (Nilsen & Brinton, 2002a; 
Nilsen & Brinton, 2003). In addition, progesterone protected against kainic acid-induced 
neuronal loss in vitro whereas MPA did not (Ciriza, Carrero, Frye, & Garcia-Segura, 2006). 
Treatment with estradiol and progesterone but not MPA, increased proliferation of 
neuroprogenitor cells in culture (L. Liu et al., 2010). Furthermore, MPA decreased levels of 
brain-derived neurotrophic factor while progesterone increased this measure (Jodhka, Kaur, 
Underwood, Lydon, & Singh, 2009). MPA, but not progesterone, significantly decreased levels 
of glutamic acid decarboxylase in the hippocampus (Braden et al., 2010), and suppressed 
cytokine production after an inflammatory stimulus in vitro (Bamberger, Else, Bamberger, Beil, 
& Schulte, 1999). Most of these studies have examined the effects of acute progestogen 
treatment and the current study administered hormones for approximately seven months in order 
to evaluate the long-term effects of hormone treatment. It has been found that chronic treatment 
of ovarian hormones results in different outcomes than more acute treatments (Gibbs, 1997; 
Morissette & Di Paolo, 1993; Pazol, Northcutt, Patisaul, Wallen, & Wilson, 2009). The long-
term hormone treatment used in the current study may result in receptors that are less sensitive 
and the two progestogens may result in differential receptor sensitivities after long-term 
exposure.  
 The mPFC in rodents plays a role in higher-order cognitive behaviors such as working 
memory and behavioral flexibility (Birrell & Brown, 2000; De Bruin et al., 2000; Kolb, 1990).  
Many of these behaviors are impaired during aging. For example, aged rats showed decreased 
performance, as compared to young rats, on object recognition (Wallace et al., 2007) and delayed 
spatial alternation tasks (Ando & Ohashi, 1991; Tanila, Taira, Piepponen, & Honkanen, 1994). 
There is evidence that performance on tasks mediated in part by the PFC is correlated with 
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dopamine levels in the PFC of aged female rats (Luine, Bowling, & Hearns, 1990) and tyrosine 
hydroxylase fibers in the male mPFC (Mizoguchi et al., 2009). Therefore, the greater amount of 
tyrosine hydroxylase found in the mPFC in the current study would be expected to result in 
improved performance on tasks mediated by the prefrontal cortex.  Indeed, our lab has shown 
previously that long-term treatment with estradiol and MPA improved acquisition of the t-maze 
in aged female rats (Chisholm & Juraska, 2012). However, when a subset of these animals was 
tested on the water-maze, this same treatment impaired performance as compared to all other 
hormone treated groups (Lowry, Pardon, Yates, & Juraska, 2010).  Interestingly, estradiol 
treatment affects monoamine levels differently in the PFC and the hippocampus. Estradiol 
increased levels of monoamines in the PFC but decreased them in the hippocampus of young 
adult animals (Inagaki et al., 2010). The water-maze is thought to be heavily mediated by the 
hippocampus, while several brain regions are important for t-maze performance including the 
PFC and striatum (Lalonde, 2002; Redish & Touretzky, 1998). Although the current study did 
not look at tyrosine hydroxylase densities in the hippocampus, it is possible that estradiol in 
combination with MPA does not alter dopamine in the hippocampus providing an explanation 
for the differential behavioral outcomes observed in our previous studies.  
Tyrosine hydroxylase is the rate limiting enzyme in the biosynthesis of catecholamines 
and therefore identifies both dopaminergic and noradrenergic fibers. However, there is evidence 
that suggests the changes found in the current study are primarily dopaminergic. Studies using 
dopamine β hydroxylase (DBH), a marker for adrenergic and noradrenergic fibers, in the primate 
prefrontal cortex have found a low density of fibers that were large in diameter whereas tyrosine 
hydroxylase staining was dense and labeled slender highly varicose axons (Lewis, Foote, 
Goldstein, & Morrison, 1988; Lewis & Morrison, 1989). There also appears to be distinct 
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morphologies between DBH and tyrosine hydroxylase fibers in rodents. When noradrenergic 
fibers were selectively depleted in the anterior cingulate of the rat, the remaining fibers were 
characterized as thin delicate fibers with many varicosities and presumed to be dopaminergic 
(Berger, Tassin, Blanc, Moyne, & Thierry, 1974). The fibers that were observed in the current 
study were thin and highly varicose more closely resembling those previously described as 
dopaminergic. Importantly, ovariectomy has been shown to increase DBH labeled fibers in the 
prefrontal cortex and this was reversed after estrogen or estrogen with progesterone treatment 
(Kritzer & Kohama, 1999). Based on this, any staining of noradrenergic fibers in the current 
study would be expected to increase the number of fibers in our ovariectomized animals and 
therefore underestimate the effects of hormone treatment observed on tyrosine hydroxylase 
fibers. 
Long-term hormone treatment did not alter neuron number in the mPFC. Thus the 
preservation of the number of mPFC neurons in intact aging females compared to males 
observed by Yates et al. (Yates et al., 2008) is not accounted for by the hormone replacement 
regiment given here.  These results may seem surprising due to the numerous studies that have 
demonstrated that estrogens are neuroprotective in young animals and in vitro (Garcia-Segura et 
al., 2001).  However, there is a growing body of research indicating that the adult brain and aged 
brain respond differently to hormone treatments. For example, estrogen treatment reduced 
cortical infarct volume in young adult animals, but resulted in greater infarct volume in middle-
aged animals (Selvamani & Sohrabji, 2010b). While replicating this finding, a follow up study 
found that estrogen treatment increases levels of IGF-1 in young animals, while decreasing levels 
in middle-aged animals (Selvamani & Sohrabji, 2010a). Therefore it is important that studies 
examining the effects of hormone treatments on problems associated with aging do so in an 
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appropriate model. In addition, it is unknown how neuroprotective properties seen after extreme 
insult relate to normal aging.  
This is the first study to find that long-term treatment with estradiol alone or in 
combination with MPA alters the prefrontal dopaminergic system during aging. Because the 
deterioration of the dopaminergic system during normal aging is correlated with decreased 
performance on cognitive tasks, the results provide a possible mechanism by which hormone 
treatments could benefit cognition during aging.  
  
 Figure 11.
Figure 11.  A. Tyrosine hydroxylase immunostained
compressed using Axiovision software. Image pixel density (the percent of the image in black) 
was measured in two ways: first as a binary image (B), taking thickness into account, and then as 
a skeletonized image (C), reducing the thickness to 1 pixel wide.
 
 
Figure 12. 
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Figure 12. The total number of neurons in the mPFC (mean+ SEM). There was not a significant 
effect of hormone treatment on neuron number.  
 
Figure 13.
 
Figure 13. The density of TH fibers in Layer 1 (mean+ SEM). (A) In binary images, there was an 
effect of hormone treatment in (p< .03). (B) In skeletonized images, there was a trend for an 
effect of hormone treatment in (p< .09) * (p < .05), # (p = .06) $ (p <.08). 
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Figure 14. 
 
Figure 14. The volume of TH fibers (mean+ SEM) within the mPFC. In layer 1 (A) (p<.03) and 
layers 2/3 (B) (p<.04) there was an effect of hormone treatment. * (p <.02), # (p < .07). 
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Figure 15.
 
Figure 15. The density of TH fibers in layers 2/3 (mean+ SEM). In binary images (A) there was 
an effect of hormone treatment (p <.05). In skeletonized images (B), there was an effect of 
hormone treatment in Layers 2/3 (p < .01). * (p < .05), # (p < .06).  
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Figure 16.  
 
Figure 16. The correlation of the volume of tyrosine hydroxylase and synaptophysin labeled 
boutons in layers 2/3 of the medial prefrontal cortex (r =.44, p< .05) 
 
Table 4. Mean Body and Uterine Weight for all subjects 
Hormone Group Mean Body Weight (g) Mean Uterine Weight (g) 
No replacement 585.2 ± 21.9 .09 ±.01 
Estradiol 454.1 ± 27.6* .16 ±.02* 
Estradiol & P 458.4 ± 28.3* .12 ± .01* 
Estradiol & MPA 404.7 ± 28.3* .16 ± .02* 
 
Body and uterine weights were taken at sacrifice for all groups. No replacement animals weighed 
significantly more and had lower uterine weights that all hormone treated groups. * p <.01   
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CONCLUSIONS 
After the negative results from the Women’s Health Initiative many women and healthcare 
providers questioned the benefits of hormone replacement therapies.  However since this time, it 
has become evident that the timing of hormone initiation is critical for the beneficial effects of 
hormone treatment, an idea now known as the window of opportunity  
The series of experiments conducted for this dissertation found no adverse effects of any 
hormone combination started in middle age when compared to control animals. In fact, a 
beneficial effect of estrogen in combination with MPA was found for several measures including 
acquisition of a delayed alternation task and synapse number and tyrosine hydroxylase fiber 
density in the mPFC. Although this series of experiments did not directly examine the window of 
opportunity, it does add to the literature showing beneficial effects of hormone treatment when it 
is initiated soon after the loss of naturally circulating hormones. The studies presented here are 
the first to examine the long-term effects of estrogen in combination with MPA and the 
beneficial outcomes found in the current experiments highlight the need for future studies 
examining the cognitive and neural effects of this hormone treatment. Given the differences in 
how the hippocampus and mPFC age, it would be important to determine if estrogen in 
combination with MPA has similar effects on these two brain regions during aging. 
 In addition, whereas many studies in young animals find beneficial effects of estrogen only 
treatments, this series of experiments found that the addition of MPA led to a greater effect than 
estrogen only.  As discussed in previous chapters, there are many changes that occur during 
aging and therefore it is not reasonable to expect similar effects in the young and aged brain. 
Because of this, future studies should use aging animals when attempting to model the effects of 
hormone treatments during menopause. 
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